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1. INTRODUCTION 
 
1.1  INTRODUCTION OF PARENTERALS1 
 The parenteral administration route is the most effective and common form 
of delivery for active drug substance with poor bio availability and the drugs with a 
narrow therapeutic index. These products are intended for administration by 
injection.  
1.1.1  Types of Parenteral 
 Parenterals are broadly classified into three types 
a)  Small volume parenterals(SVP) 
 All the sterile products packaged in vials, ampoules, cartridges, syringes 
bottles or other container that is 100 ml or less fall under the class of SVP 
b)  Large volume parenterals(LVP) 
 The USP provides the definition for large volume parenteral (LVP) “ where 
used in the pharmacopeia, the designation large volume solutions applies to an 
injection that is intended for intravenous use and is packaged in containers holding 
100 ml or more”. LVP’S means a terminally sterilized aqueous drug product 
packaged in a single dose container with a capacity of 100 ml or more and intended 
to be administered or used in humans. It includes IV infusions, irrigation solutions, 
peritoneal dialysates and blood collecting units with anticoagulants. 
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1.1.2  Route of Administration1 
Figure 1 
 
 
 
 
 
Table 1 
Route Injection site 
Intravenous (IV) Vein  
Intramuscular (IM) Muscle tissue 
Intradermal (ID) Dermis of the skin 
Subcutaneous (subcut: SQ) Subcutaneous tissue of the skin 
Intrathecal (IT) Subarachnoid space of the spinal cord 
Epidural  Epidural space of the spinal cord 
Intra-arterial  Artery 
Intra- articular  Joint space 
Intracardiac Heart 
Intraocular  Eye  
Intraperitoneal Peritoneal cavity  
 
1.1.3  Advantages 
¾ Provides drug and nutritional options for patients unable to tolerance 
oral therapy. 
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¾ Circumvents absorption limitations of gastrointestinal tract. 
¾ Quick onset of action. 
¾ Localized delivery. 
¾ Prolonged duration of effect. 
1.1.4  Disadvantages  
¾ Difficulty/ impossibility of drug removal /reversal. 
¾ Risk of infection. 
¾ Risk of emboli. 
¾ Risk of hypersensitivity reactions.  
¾ Higher costs. 
1.2  LYOPHILIZATION2 
 Nowadays, in the pharmaceutical field, there is a great number of 
substances which need to be stored in a dry state due to their instability in the 
presence of water, for example, the antibiotics, vaccines, peptides and proteins. 
Lyophilization or Freeze-Drying, fills an important need in pharmaceutical 
manufacturing technology by allowing drying of heat-sensitive drugs and biological 
at low temperature under conditions that allow removal of water by sublimation, or a 
change of phase from solid to vapour without  passing through the liquid phase. 
While the most common application of pharmaceutical freeze-drying is in the 
production of injectable dosage forms, the process is also used in the production of 
diagnostics and, occasionally, for oral solid dosage forms where a very fast 
dissolution rate is desired.1 About 50% of the currently marketed biopharmaceuticals 
are lyophilized, representing the most common formulation strategy.2 
1.3 DEFINITION OF LYOPHILIZATION3-9 
 In simple terms, Lyophilization or Freeze-Drying is a unit operation in 
which water or solvent is removed from a product after it is frozen and placed under 
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a vacuum, allowing the ice to change directly from solid phase to vapor without 
passing through a liquid phase (sublimation).In this process, the moisture content of 
the product is reduced to such a low level that does not support biological growth or 
chemical reactions.  
1.4  PRINCIPLE OF LYOPHILIZATION 
 The main principle involved in Lyophilization is a phenomenon called 
Sublimation, where water passes directly from solid state (ice) to the vapor state 
without passing through the liquid state.  
The phase diagram of water show that two phases coexist along a line under 
the given conditions of temperature and pressure, while at the triple point (0.0075 °C 
at 0.61kPa or 610 Nm-2; 0.01 °C at 0.00603 atm; 0.0099°C and 4.579 mm of Hg), all 
three phases coexist. 
 
 
 
 
 
 
 
 
Figure 2 Phase diagram showing the triple point of water 
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 Lyophilization is performed at temperature and pressure conditions below 
the triple point, to enable sublimation of ice. The entire process is performed at low 
temperature and pressure, hence is suited for drying of thermolabile compounds. 
LYO lab lyophilizer is used for present study. 
 
 
 
 
 
 
 
Figure 3 LYO lab Lyophilizer used for the present study 
 
 
 
 
 
 
 
Figure 4  Vials typically used for Lyophilization showing slotted stopperIn the 
open and closed positions 
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1.5  STAGES OF FREEZE DRYING10 
 A typical freeze-drying process consists of three separate, unique and inter-
dependent processes namely  
y Freezing (solidification) 
y Primary drying (sublimation) 
y Secondary drying (desorption) 
1.5.1  Freezing 
 Freezing is generally the first step in a freeze-drying process, in which 
nearly  90%  of  the  water  is  converted  to  ice  crystals  while  all  solutes  in  the  
formulation are solidified into a matrix either in amorphous or crystalline state, or in 
a mixture. The conversion from water to ice crystals starts with ice nucleation, 
which is followed by ice crystal growth. For a typical pharmaceutical formulation, 
the ice nucleation temperature is often in the range of 10–15ºC or more below the 
equilibrium freezing point; a phenomenon referred to as Super-Cooling.  
 Products freeze in two ways, depending on the makeup of the product. The 
majority of products that are subjected to freeze drying consist primarily of water, 
the solvent, and the materials dissolved or suspended in the water, the solute.It is 
very important in freeze drying to refreeze the product to below the eutectic 
temperature before beginning the freeze drying process. Small pockets of unfrozen 
material remaining in the product expand and compromise the structural stability of 
the freeze dried product. 
 The second type of frozen product is a suspension that undergoes glass 
formationduring the freezing process. Instead of forming eutectics, the entire 
suspension becomes increasingly viscous as the temperature is lowered. Finally the 
product freezes at the glass transition pointforming a vitreous solid. This type of 
product is extremely difficult to freeze dry.10 
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a)  Process Design and Control 6 
 During freezing, the chamber pressure is slightly lower than the 
atmospheric pressure due to low temperature, or/and pre reduction of chamber 
pressure to enhance the sealing of the chamber door. The stage of the process is 
generally controlled by the shelf-cooling/heating rate, shelf-holding temperatures, 
and holding times.  
b)  Pre freezing hold 
 In order to facilitate relatively uniform ice nucleation and ice crystal 
growth, the product vials on the shelf are held at a temperature lower than room 
temperature before cooling down. This temperature is generally the loading 
temperature, for example, 5ºC. For formulations with high super-cooling 
temperature, holding at an even lower temperature (a few degrees higher than the ice 
nucleation temperate) is more appropriate. 
c)  Cooling Down to the Final Freezing Temperature 
 Cooling the product to a terminal (final) freezing temperature facilitates the 
ice nucleation/growth and solute solidification. If a super-cooling hold is applied, a 
relatively faster cooling is generally helpful for intra-vial uniformity of ice 
formation. 
d)  Annealing11 
 Annealing is simply holding the product at a temperature above the final 
freezing temperature for a defined period to crystallize the potentially crystalline 
components (usually, crystalline bulking agent) in the formulation during the 
freezing stage. An annealing step is frequently necessary to allow efficient 
crystallization of the crystalline bulking agent, such as mannitol or glycine. Failure 
to crystallize the bulking agent if bulking agent crystallizes during primary drying, 
vial breakage may result, which is common if a high fill depth of concentrated 
mannitol is used.Vial breakage can be prevented by crystallization of 
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mannitolduring freezing using slow freezing or by avoiding a temperature lower 
than about í25°C until the mannitol has completely crystallized. Completion of 
crystallization may be facilitated by annealing. After annealing, the product 
temperature is generally lowered to a final temperature and held long enough to 
complete solidification. 
1.5.2 Primary Drying 10 
 After freezing, the productis ‘‘dried’’ at relatively low temperature and low 
pressure in which ice can be removed from the frozen product via sublimation, 
resulting in a dry, structurally intact product. 
This requires very carefully control of the two parameters, 
1)  Temperature and 
2)  Pressure involved in freeze-drying system. 
 It is extremely important that the temperature at which a product is freeze-
dried is balanced between the temperature that maintains the frozen integrity of the 
product and the temperature that maximizes the vapor pressure of the product. This 
balance is key to optimum drying. 
 Energy supplied to sublime a gram of water from the frozen to the gaseous 
state as is (2700 joules per gram of ice). 
1.5.2.1  Process design principle 
a)  Heat Transfer  
 Heat transfer in lyophilization can occur by three processes: conduction, 
convection and radiation. Of these, Conduction is the main contributor to the heat 
transfer.  
 
9 
 
Conduction can be modeled by Fourier's law: 
  
 Where the heat flow is dQ/dt, A is the area of the surface, Ȝ is the thermal 
conductivity of the material and dTis the temperature gradient across the thickness 
of the material dz. 
 Radiation heat transfer must also be taken into account in lyophilization. 
This is the transfer of heat by electromagnetic radiation. A real body emits and 
absorbs radiation according to the equation: 
  
 Where e = emissivity, ı = Stefan-Boltzmann constant and T = Absolute 
Temperature. 
b)  Mass Transfer 11 
 The rate at which the ice sublimes will be affected by the resistances that it 
encounters. The heat and mass transfer causes the top of the product to dry first with 
drying proceeding downward to the bottom of the vial. Therefore, as drying 
proceeds, there exists a three component or layer system in each vial – the upper dry 
product, the middle sublimation front, and the lower frozen liquid product. As the 
dried layer increases, it becomes a great barrier  
 Or the source of greatest resistance to the transfer of mass out of the vials. 
10 
 
 
Figure 5 Resistances and their relative contributions in Mass Transfer 
1.5.2.2  Process design and control12 
a)  Target Product Temperature and Structural Collapse 
y Collapse temperature for an amorphous system refers to the 
temperature, above which the dried region adjacent to ice loses its 
structure,that is; collapse temperature (Tc) can be higher than the glass 
transition temperature (Tg). 
y A safety margin should be kept during primary drying, that is, the 
product temperature (Tp) should be 2–5ºC below Tc or Te. This safety 
margin accounts for (i) the product temperature increases, in general, 
between 1 and 3ºC, due to the increase of resistance from the dried-
layer as drying progresses; (ii) the heterogeneity of product temperature 
across the shelf and from shelf to shelf. 
b)  Chamber Pressure 
y A most efficient primary drying condition for the product in a given 
vial should be a combination of a ‘‘very high’’ shelf temperature with a 
‘‘very low’’ chamber pressure. 
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y  The chamber pressure is not generally lower than 50 mTorr. 
y As a general rule, a chamber pressure, approximately between 10% and 
50% of ice vapor pressure at the target product temperature, which 
generally falls into a range between 50 and 200 mTorr is chosen for 
primary drying. This moderate chamber pressure (100–150 mTorr) 
gives optimal homogeneity of heat transfer in a set of vials.25 
Therefore; the optimum chamber pressure is a compromise between 
high sublimation rate and homogenous heat transfer. 
y The optimal chamber pressure at known target product temperature (Tp) 
can be given by the equation 
۾܋ = ૙.૛ૢ × ૚૙(૙.૙૚ૢ×܂ܘ)  
Where  Pc is chamber pressure (Torr) and Tp is product temperature (°C). 
c) Shelf Temperature 
x Shelf temperature can be determined experimentally by manometric 
temperature measurement (MTM),12 
y The shelf temperature is higher than the product temperature and 
sometimes can be much higher, up to 40ºC. 
 
1.5.2.3  Process monitoring and control 6 
a)  Determination of End Point of Primary Drying 
 Once the shelf temperature and chamber pressure for primary drying are 
determined, the primary drying process, essentially including two steps 
b)  Ramp from Freezing to Primary Drying: 
 After evacuation to reduce the chamber pressure to the target level, the 
shelf temperature is ramped up to the target value. The ramp rate should not be too 
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high, normally less than 1ºC/min. During this initial period of sublimation, ice 
sublimation rate can be quite high, since the resistance in the product is nearly zero. 
c)  Duration of Primary Drying: 
 The duration of primary drying is determined by the ice sublimation rate, 
the characteristics of formulation solution and can be roughly estimated  
x Theoretically by calculations based upon the mass and heat transfer 
equations. 
x In practice, the duration is determined by monitoring the drying 
progression. 
1.5.3 Secondary Drying 
 When all ice crystals are removed from the product by sublimation, the 
dried product contains a fairly high amount of ‘‘unfrozen water’’ (5–20% in the 
solid content). In the secondary drying stage, the unfrozen water is further reduced 
to a desired, much lower level at a higher temperature. 
 The glass transition temperature (Tg) of the dried formulation is a function 
of the moisture content, which is governed by the Gorden-Taylor equation. 
Therefore, the Tg changes sharply with the decrease of moisture during the ramp 
from primary drying to secondary drying, and during secondary drying. 
1.5.3.1  Process design and control13 
a)  Heating Rate and Chamber Pressure 
y Because of the fairly high residual moisture content in the amorphous 
product early in secondary drying and, thus, low glass transition 
temperature, the potential for collapse is greatest early in secondary 
drying. So a ramp rate of 0.1 or 0.15°C/min for amorphous products is 
generally safe and appropriate. 
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y Crystalline products do not have any potential for collapse during 
secondary drying, and a higher ramp rate is suggested for such products 
(0.3 or 0.4°C/min). 
y The chamber pressure in primary drying is also appropriate for 
secondary drying, it is not necessary to change chamber pressure for 
secondary drying. 
b)  The Shelf Temperature and Secondary Drying Time14 
y The products should be kept at “high” temperature for a period 
sufficient to allow the desired water desorption. Usually, it is better to 
run a high shelf temperature for a short time than a low temperature 
for a long period.  
y Amorphous products are more difficult to dry than crystalline 
products. Thus, higher temperatures and longer times are needed to 
remove the absorbed water. 
y The secondary drying conditions also depend on the solute 
concentration. At higher solute concentration (i.e., >10% solids in 
solution), the dry product has smaller specific area, and it is more 
difficult to remove the absorbed water; thus longer times and/or higher 
temperatures are needed to finish secondary drying. 
y Normally, drying times of 4–10 h at the range 40 to 50°C. 
y The optimum secondary drying time can be determined by real-time 
residual moisture measurement using Karl Fischer titration (KF), 
thermal gravimetric analysis (TGA), or near IR spectroscopy.15 
 
14 
 
 The product is usually freeze dried to very low residual moisture content 
(about  0.5%).  Usually,  a  combination  of  long  drying  times  (6  h)  and  low  shelf  
temperature (about 0°C) are best, but the exact conditions must be determined by 
trial and error. 
 
 
 
 
 
 
 
Figure 6  Plot of process variables such as shelf temperature, product 
temperature and vacuum level in chamber during freeze-drying 
cycle. 
1.6 EXCIPIENTS USED IN LYOPHILIZATION16 
 The International Pharmaceutical Excipients Council (IPEC) has defined 
excipients as: “…substances other than thepharmacologically active drug or 
prodrug which areincluded in the manufacturing process or are containedin a 
finished pharmaceutical product dosage form.” 
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¾ The excipients commonly used in the lyophilization have been 
 classified as: 
 
a)  Bulking agent17-19 
x Bulking agents, as the name implies, form the bulk of the lyophilized 
product and provide an adequate structure to the cake. These are 
generally used for low dose (high potency) drugs that do not have the 
necessary bulk to support their own structure. These are particularly 
more important when the total solid content is less than 2%.In such 
cases, a bulking agent is added to the formulation matrix. 
x Mannitol and glycine, are the most commonly used bulking agents, 
followed by glucose, sucrose, lactose, trehalose and dextran. 
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b) Co-Solvents20 
x Water is the most commonly used solvent for lyophilization. However, 
organic solvents are sometimes used to increase the primary drying rate 
by increasing the sublimation rates, improve product stability, decrease 
reconstitution time by improving drug wettability or solubility, and also 
enhance the sterility assurance of the sample solution. 
x The most commonly used solvent is a tertiary-butanol/water 
combination. 
Liophilization can be applied for  
¾ Non – biological where the process is used to dehydrate or concentrate 
reactive or heat labile chemicals 
¾ Non-living bioproducts 
x Enzymes  
x Hormones  
x Antibodies  
x Inactivated vaccines  
¾ Industrially useful bio products  
1.7  DESIRED CHARACTERISTICS OF FREEZE-DRIED  
 PRODUCTS6, 11 
 The desired characteristics of a freeze-dried pharmaceutical dosage form 
include: 
x A freeze dried product is expected to have nearly full recovery of the 
original chemical or biological potency after reconstitution 
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x Cake should be intact occupying the same shape and size as the 
original frozen mass 
x Have sufficient mechanical strength to prevent cracking, powdering or 
collapse 
x Uniform colour and pharmaceutically elegant appearance 
x The product should be sufficiently dry to maintain stability and 
sufficiently porous which leads to rapid and complete dissolution 
x The product should be free from microorganisms, pyrogens and 
particulates 
 The desired characteristics can be achieved by proper formulation of the 
product and by employing optimum freeze-drying cycles. 
1.8 ADVANTAGES OF LYOPHILIZATION 7, 11 
 The principle advantages of lyophilization includes 
x Minimum damage and loss of activity in delicate heat-labile materials 
x Removal of water without excessive heating of the product 
x Enhanced product stability in a dry state 
x Rapid and easy dissolution of reconstituted product due to the porous 
nature of the product 
x Good for oxygen and/or air-sensitive drugs 
x Sterility of product can be achieved and maintained 
x Constituents of the dried material remain homogenously dispersed 
x Reduced weight of the product which makes the product easier to 
transport 
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1.9  DISADVANTAGES OF LYOPHILIZATION 7, 20 
x Increased handling and processing time 
x Need for sterile diluent upon reconstitution 
x Cost and complexity of equipment 
1.10  FINISHED PRODUCT INSPECTION - MELTBACK 
 The USP points out that it is good pharmaceutical practice to perform 
100% inspection of parenteral products. This includes sterile lyophilized powders.  
1)  Melt back is a form of cake collapse and is caused by the change from 
the solid to liquid state. That is, there is incomplete sublimation 
(change from the solid to vapor state) in the vial. Associated with this 
problem is a change in the physical form of the drug substance and/or a 
pocket of moisture. These may result in greater instability and 
increased product degradation. 
2) Another problem may be poor solubility. Increased time for 
reconstitution at the user stage may result in partial loss of potency if 
the drug is not completely dissolved, since it is common to use in-line 
filters during administration to the patient. 
 Manufacturers should be aware of the stability of lyophilized products 
which exhibit partial or complete meltback. Literature shows that for some products, 
such as the cephalosporins, that the crystalline form is more stable than the 
amorphous form of lyophilized product. The amorphous form may exist in the 
"meltback" portion of the cake where there is incomplete sublimation 
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Table 2Marketed lyophilized formulations10 
DRUG CATEGORY MARKETED NAME 
MANUFACTUR
ER 
Amifostine Cytoprotective 
agent 
Ethyol® MedImmune 
Oncology 
Amphotericin B Antifungal Ambisome® Astellas 
Acyclovir sodium Antiviral Zovirax® GlaxoWellcome 
Azithromycin Antibiotic Zithromax® Pfizer 
Cefazolin sodium Antibiotic Ancef ® GlaxoSmith-Kline 
Chlorothiazide 
sodium 
Diuretic and 
hypertensive 
Diuril® 
 
Merck 
Cisplatin Antineoplastic Platinol® Bristol Myers 
Oncology 
Dantrolene sodium Muscle relaxant Dantrium® Procter & Gamble 
DaunorubicinHCl Antibiotic Cerubidine® Bedford 
Diltiazem Antianginal Cardizem® 
 
Hoechst Marion 
Roussel 
Doxorubicin HCl Antineoplastic Rubex® Bristol Myers 
Squibb 
Ganciclovir sodium 
 
Treatment of CMV 
retinitis in 
immunocompromiz
ed patient 
Cytovene® Roche 
HydromorphoneHCl Opioid analgesic Dilaudid-HP® Abbott 
Lansoprazole Proton pump 
inhibitor 
Prevacid® TAP 
Metronidazole Antibacterial Flagyl® Pfizer 
Mitomycin Antineoplastic Mutramycin® 
 
Bristol Myers 
Squibb 
Pentostatin Antineoplastic Nipent® Supergen 
Phentolaminemesyla
te 
Antihypertensive Regitine® Novartis 
Pralidoxime chloride 
 
Antidote for 
overdose due to 
anticholinesterase 
Protopam® Baxter 
Healthcare 
Tazobactam sodium 
and 
Piperacillin sodium 
Antibacterial 
combination 
Zosyn® Lederle 
Tigecycline Antibacterial Tygacil® Wyeth 
VancomycinHCl Antibiotic VancocinHCl® Eli Lilly 
Vecuronium bromide Muscle relaxant Norcuron® Organon 
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2. LITERATURE REVIEW 
 
 Julia CK et al., (2011)explained that Lyophilization is a drying process in 
which freezing step is an important step, that impacts both process performance and 
product quality. In this review, the physico-chemical fundamentals of freezing are 
first summarized. The available techniques that can be used to manipulate or directly 
control the freezing process in lyophilization are also reviewed. It aims to provide an 
awareness of not only the importance but also the complexity of the freezing step in 
lyophilization and its impact on quality attributes of biopharmaceuticals and process 
performance. With a deeper understanding of freezing and the possibility to directly 
control or at least manipulate the freezing behavior, more efficient lyophilization 
cycles can be developed and the quality and stability of lyophilized 
biopharmaceuticals can be improved.21 
 Nishant Tet al., (2010)explained about the Background of Bendamustine 
(Treanda, Ribomustine), as a water-soluble, bifunctional chemotherapeutic agent 
that also has potential antimetabolite properties. He also stated that the 
Bendamustine has been designated as an orphan drug in the United States, 
conferring prolonged market exclusivity. This article provides a comprehensive 
review of the data on efficacy and toxicity from trials investigating the use of 
bendamustine for the treatment of lymphoproliferative neoplasms.22 
  Nazik  Eet al., (2010)explained that Flutamide (FLT), an anticancer drug 
for prostatic carcinoma, has poor aqueous solubility and low oral bioavailability. 
The present research describes the ability of ȕ-cyclodextrins(ȕ-CD) and 
hydroxypropyl-ȕ-cyclodextrin (HP-ȕCD) to form complexes with Flutamide with 
enhanced solubility and dissolution rate in vitro. FLT–CD lyophilized dispersions 
(LDs) were prepared via Lyophilization monophase solution technique using tertiary 
butyl alcohol (TBA) as a co solvent. This shows an AL-type phase solubility 
diagram consistent with a linear increase in drug solubility as a function of CD 
concentration. Based on the data from differential scanning calorimetry (DSC) and 
X-ray diffractometry (XRD), FLT was fully amorphous in 1:5 FLT-HP-ȕ-CD LD as 
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indicated by complete disappearance of FLT endothermic and diffraction peaks. The 
Fourier transform infrared (FTIR) spectra indicated that a FLT–CD interaction took 
place in the lyophilized complex. These data suggest that cyclodextrins might be 
useful adjuncts in preparation of immediate-release formulations of FLT.23 
 Meister E et al., (2006) studied the dependency of a collapse temperature 
(Tc) on total solid content by evaluating physical properties (e.g. viscosity) of 
selected excipients solutions at 0°C. Thus, to gain a better understanding of collapse 
behavior and therefore the opportunity to further optimize formulations and freeze 
drying cycles and to evaluate the transferability of collapse temperatures measured 
by Freeze Drying Microscopy (FDM) on freeze drying processes, and to establish a 
general relationship (guideline) between the onset of collapse as detected by 
microscopy and actual (micro) collapse of a structure in a vial during a freeze drying 
cycle.24 
 Shailaja Ret al., (2005) the purpose of the present studies was to investigate 
the effect of shelf temperature during primary drying and secondary drying on the 
degree of cake shrinkage. Freeze drying experiments are performed using 5%w/v 
sucrose where the drying protocols are altered in order to produce differing product 
temperature profile. Resistance data during freeze-drying are evaluated by the 
Manometric Temperature Measurement (MTM) Method. Theoretical simulation of 
the freeze drying process is performed using the passage freeze-drying Software. 
The difference between the glass transition temperature and product temperature 
(Tg-T) obtained from the theoretical analysis is calculated and used for correlation 
with experimental shrinkage data. Conclusion of experiment is maintained well 
below the collapse temperature and below glass transition temperature throughout 
the drying process which is important for prevention of shrinkage.25 
 Jennings TAet al.,(2005)examines means for managing the risk that the 
moisture from elastomer closures may have in producing poor lyophilized products. 
Assessment of the risk will be based on the frequency distribution of the capacitance 
of the closures. The importance that the sample size will have on confidence interval 
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and its effect on managing the risk will be examined. Other key factors that must be 
taken into account are post lyophilization treatment of the closures and mass of the 
lyophilized cake. Sound management of the risk of a poor lyophilized product from 
the residual moisture of closures requires a reliable data base.26 
 Searles JAet al.,(2004) performed research on annealing to optimize the 
primary drying rate, reduce freezing-induced drying rate heterogeneity, and 
determined Tg in pharmaceutical lyophilization.27 
 Rambhatla Set al., (2004)studied heat and mass transfer scale-up issues 
during freeze drying: control and characterization of the degree of super cooling.28 
 Tsinontides SCet al., (2004)showed thatFreeze Drying involves transfer of 
heat and mass to and from the product under preparation, respectively, thus it is 
necessary to scale these transport phenomena appropriately from pilot plant to 
manufacturing-scale units to maintain product quality attributes. It also describes the 
principal approach and tools utilized to successfully transfer the lyophilization 
process of a labile pharmaceutical product from pilot plant to manufacturing. Based 
on pilot plant data, the lyophilization cycle is tested during limited scale-up trials in 
manufacturing to identify parameter set-point values and test process parameter 
ranges. The limited data from manufacturing are then used in a single-vial 
mathematical model to determine manufacturing lyophilizer heat transfer 
coefficients, and subsequently evaluate the cycle robustness at scale-up operating 
conditions. The lyophilization cycle is then successfully demonstrated at target 
parameter set-point values.29 
 Edinara AB et al., (2004)described thatFreeze drying is a separation 
process based on the sublimation phenomenon. This process has the following 
advantages compared to the conventional drying process. The material structure is 
maintained, moisture is removed at low temperature (reduced transport rates), 
product stability during the storage is increased, and the fast transition of the 
moisturized product to be dehydrated minimizes several degradation reactions. In 
order to put it to practice, a mathematical model based on fundamental mass and 
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energy balance equations has been developed, based on a deterministic mathematical 
model proposed by Liapis and Sadikoglu [Drying Technol.(1997) 791], and used to 
calculate the amount of removed water and amount of residual water. The 
optimization  procedure  showed  to  be  an  important  tool  to  improve  the  process  
performance since lower energy consumption and hence lower cost has been 
achieved to obtain the product with the same quality.30 
 Vikas KS et al., (2004)studied the systematical investigation of protein-
Mannitol interactions using vacuum drying, to obtain a better understanding of the 
effect of protein/Mannitol w/w ratios on the physical state of Mannitol and protein 
secondary structure in the dried state. Solutions containing ȕ-lacto globulin (ȕLg): 
Mannitol (1:1-1:15 wt/wt) are vacuum dried at 5°C under 3000 mTorr pressure. The 
physical state of Mannitol is studied using x-ray powder diffractometry (XRPD), 
polarized light microscopy (PLM), Fourier-transform infrared (FTIR) spectroscopy, 
and modulated differential scanning calorimetry (MDSC). XRPD studies indicate 
that Mannitol remained amorphous up to 1:5 w/w ȕLg, Mannitol ratio, whereas 
PLM showed the presence of crystals of Mannitol in all dried samples except for the 
1:1 wt/wt ȕLg: Mannitoldried sample. FTIR studies indicated that a small proportion 
of crystalline Mannitol is present along with the amorphous Mannitol in dried 
samples at lower (less than 1:5 wt/wt) ȕLg: Mannitol ratios. The Tg of the dried 1:1 
wt/wt ȕLg: Mannitol sample was observed at 33.4°C in MDSC studies, which 
indicates that at least a part of Mannitol co-exist with protein in a single amorphous 
phase.31 
 Zhai S et al., (2003)studied to explain the mass transfer processes that 
influence the rate of primary drying during lyophilization. They showed that the 
total  time  required  to  sublime  water  from  aqueous  slurries  of  glass  beads  in  a  
conventional laboratory lyophilizer are in reasonable agreement with those times 
estimated using the values determined by freeze-drying miscroscopy.32 
 Nail.S.Let al., (2002) explained the principles involved, process 
development methods, advantages, disadvantages and applications of freeze drying 
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and described about different freeze drying equipments, and pharmaceutical and 
biological products that can be lyophilized by freeze drying process.33 
 Teagarden DL et al., (2002)studied thatNon-aqueous co-solvent systems 
have been evaluated for their potential use in the freeze-drying of pharmaceutical 
products. The advantages of using these non-aqueous solvent systems include 
increased drug wetting or solubility, increased sublimation rates, increased pre-dried 
bulk solution or dried product stability, decreased reconstitution time, and 
enhancement of sterility assurance of the pre-dried bulk solution. Conversely, the 
potential disadvantages and issues which must be evaluated include the proper safe 
handling and storage of flammable and/or explosive solvents, the special facilities or 
equipment which may be required, the control of residual solvent levels, the toxicity 
of the remaining solvent, qualification of an appropriate GMP purity, the overall 
cost benefit to use of the solvent, and the potential increased regulatory scrutiny. The 
co-solvent system that has been most extensively evaluated is the tert-butanol/water 
combination. The tert- butanol possesses a high vapor pressure, freezes completely 
in most commercial freeze-dryers, readily sublimes during primary drying, can 
increase sublimation rates, and has low toxicity. This co-solvent system has been 
used in the manufacture of a marketed Injectable pharmaceutical product. When 
using this solvent system, both formulation and process control requires 
optimization to maximize drying rates and to minimize residual solvent levels at the 
end of drying. Other co-solvent systems which do not freeze completely in 
commercial freeze-dryers are more difficult to use and often resulted in unacceptable 
freeze-dried cakes. Their use appears limited to levels of not more than 10%.
34
 
 SchoenaMPet al.,(1999)studied a lyophilization process model which is 
adapted to fit experimental data from product vials processed using a development 
scale dryer. The model is evaluated with regard to how well it is simulated with the 
primary drying time and temperature conditions for product vials during the primary 
drying phase of the cycle. The results indicate that the predicted drying time is very 
close to the actual drying time observed for the product. The simulated product 
temperature profile is also compared well with the actual product temperature 
profile.35 
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 Liapis et al., (1995) constructed a theory to describe quantitatively the 
dynamic behavior of the primary and secondary drying stages of the freeze-drying of 
pharmaceutical crystalline and amorphous solutes. Experimental data for the freeze-
drying of cloxacillin monosodium salt and skimmed milk are obtained using a pilot 
freeze-dryer. The comparison of the theoretical results with the experimental data 
shows that the agreement between experiment and theory is good.36 
 U.S. Food and Drug Administration (USFDA) has given various 
guidelines to be followed for the successful manufacturing of parenteral 
lyophilization product. It explains bulk solution manufacturing, filling, partial 
stoppering, loading into lyophilizer and freeze drying in chamber and unloading 
from chamber and sealing and evaluation of finished product. 
26 
 
3. AIM & OBJECTIVE 
3.1  AIM  
 The  aim  of  my  present  study  was  to  formulate  a  stable  lyophilized  
formulation of Bendamustine Hydrochloride (100mg/vial) which is therapeutically 
equivalent to the innovator product, Treanda, manufactured by Cephalon. 
3.2  OBJECTIVE 
 Bendamustine Hydrochloride is an Antineoplastic agent used in the 
treatment of patients with chronic lymphocytic leukemia (CLL) and with indolent B-
cell non-Hodgkin’s lymphoma (NHL).It is under the class of alkylating agents. 
 The purpose of the present study was to formulate a stable lyophilized 
formulation of the drug Bendamustine Hydrochloride (100mg/vial).  
 Bendamustine Hydrochloride is unstable in the solution form. So, it cannot 
be formulated as a liquid dosage form. In order to improve its stability, the drug 
product should be dried and formulated as a solid product. Even though there are 
several drying techniques to dry a product, Lyophilization technique was preferred 
because it involves the drying of the product at low temperature and low pressure. 
As Bendamustine Hydrochloride is thermo labile in nature and cannot withstand 
elevated temperatures, this technique is the best choice to increase its stability. 
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4. PLAN OF WORK 
 
 To achieve the ultimate goal of formulating lyophilized product of 
Bendamustine Hydrochloride, the present work was designed to address the 
following objectives 
¾ Preformulation studies of the drug 
¾ Formulation of the injectable dosage form  
¾ Development of Lyophilization cycle. 
¾ Compatibility studies with process components 
¾ Lyophilization of the injectable dosage form 
¾ Evaluation of lyophilized product. 
¾ Comparative study with innovator product  
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5 DRUG AND EXCIPIENT PROFILE37-39 
Table 3 
Name of the Drug 
Substance 
Bendamustine Hydrochloride 
Therapeutic 
Category 
                           Antineoplastic agent 
                                                              CHEMISTRY 
Nomenclature 
 
4-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-
yl]butanoic acid 
 
Molecular formula C16H21Cl2N3O2 
Molecular weight 394.7 
Chemical category Benzimidazole derivative. 
Molecular 
structure 
 
PHYSICAL PROPERTIES 
Description White to off  white powder 
Solubility Sparingly Soluble in water, soluble in ethanol. 
Polymorphism Exists. Both crystalline and amorphous forms. 
Melting point 149-151°C 
Dissociation 
constant(pKa) 
 
4.17 
PH 
(0.5g of sample in 
25ml of carbon 
dioxide free water) 
 
2.5-3.5 
Partition 
coefficient (log P) 
1.10 
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                                           CHEMICAL PROPERTIES 
 
Spectral absorbance 
 
Maximum 275 nm 
 
Related substances 
 
Monohydroxy, IPA ester, Dihydroxy and BND-IV 
impurities. 
 
STABILITY 
Thermal stability  Unstable  
 
Photo stability 
 
Photo stable. 
 
GENERAL 
Handling 
 
Wear suitable protective clothing and gloves. 
Respiratory protection is required when dusts are 
generated. 
 
 
Storage 
 
 
Stored up to 25°C (77°F) with excursions permitted up 
to 30°C (86°F). 
 
PHARMACOLOGICAL PROPERTIES 
PHARMACOKINETICS 
Absorption 
Following a single IV dose of Bendamustine hydrochloride Cmax typically 
occurred at the end of infusion.    
Distribution 
Plasma protein binding ranges from 94% to 96%. Steady-state Vd is 
approximately 25 L. 
Metabolism 
Metabolized by hydrolysis to compounds with low cytotoxic activity, two 
active minor metabolites, M3 and M4, are formed via CYP1A2 
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Elimination 
Approximately 90% recovered in excreta, primarily in the feces. 
Bendamustine clearance in humans is approximately 700 mL/minute.  After a single 
dose of 120 mg/m2bendamustine IV over 1-hour the intermediate t½ of the parent 
compound is approximately 40 minutes.  The mean apparent terminal elimination t½ 
of M3 and M4 are approximately 3 hours and 30 minutes respectively.  Little or no 
accumulation in plasma is expected for bendamustine administered on Days 1 and 2 
of a 28-day cycle.  
Half-life 
Intermediate  half-life  of  the  parent  compound  is  40  min;  the  terminal  
elimination half-life of M3 and M4 are approximately 3 h and 30 min, respectively. 
Cl is approximately 700 mL/min. 
MECHANISM OF ACTION 
Bendamustine is a bifunctionalmechlorethamine derivative containing a 
purine-like benzimidazole ring. Mechlorethamine and its derivatives form 
electrophilic alkyl groups.  These groups form covalent bonds with electron-rich 
nucleophilic moieties, resulting in interstrand DNA cross links. The bifunctional 
covalent linkage can lead to cell death via several pathways. Bendamustine is active 
against both quiescent and dividing cells. The exact mechanism of action of 
bendamustine remains unknown.  
DOSAGE AND METHOD OF ADMINISTRATION  
Dosing Instructions for chronic lymphocytic leukemia (CLL) 
The recommended dose is 100 mg/m2 administered intravenously over 30 
minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles. 
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Dosing Instructions for B-cell non-Hodgkin’s lymphoma (NHL) 
Recommended Dosage 
The recommended dose is 120 mg/m2 administered intravenously over 60 
minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles. 
WARNINGS AND PRECAUTIONS 
Renal Function 
Use with caution in patients with mild or moderate renal impairment. Do not 
use in patients with CrCl less than 40 mL/min. 
Hepatic Function 
Use with caution in patients with mild hepatic impairment. Avoid use in 
patients with moderate to severe hepatic impairment. 
Anaphylaxis 
Anaphylaxis and anaphylactoid reactions have been reported, especially in 
the second and subsequent cycles of therapy. 
Infections  
Infections, including pneumonia and sepsis, have been reported. Patients 
experiencing myelosuppression after treatment are more susceptible to infections. 
Infusion reactions 
Reported frequently in clinical trials. Symptoms include chills, fever and 
rash. 
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Malignancies 
Premalignant and malignant diseases, including acute myeloid leukemia and 
bronchial carcinoma, myelodysplastic syndrome, and myeloproliferative disorders, 
have been reported. 
Skin reactions 
Have been reported and may include bullous exanthema, toxic skin reactions, 
and rash.  
DRUG INTERACTIONS 
Inducers of CYP1A2 (e.g., omeprazole, smoking) 
May decrease bendamustine plasma concentrations and increase levels of its 
active metabolites. Co-administer with caution. 
Inhibitors of CYP1A2 (e.g., ciprofloxacin, fluvoxamine) 
May increase bendamustine plasma concentrations and decrease levels of its 
active metabolites. Co-administer with caution. 
UNDESIRABLE EFFECTS 
Cardiovascular 
Tachycardia, Hypotension, Cardiac failure 
CNS (central nervous system) 
Fatigue, headache, dizziness, insomnia, asthenia, anxiety, depression 
Dermatological 
Rash, Pruritus , dry skin, hyperhidrosis, night sweats ,skin necrosis, skin 
reactions, including Stevens-Johnson syndrome and TEN (post marketing). 
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GI (gastro intestinal)  
Nausea  ,vomiting  ,  diarrhoea  ,  constipation,  Stomatitis  ,  abdominal  pain,  
decreased appetite , dyspepsia, gastro esophageal reflux disease, dry mouth ,oral 
candidiasis, abdominal distension, upper abdominal pain. 
Local 
1) Infusion-site pain, catheter-site pain, infusion reactions, injection-site 
irritation, pain and swelling 
Metabolic-Nutritional 
Anorexia, decreased weight, dehydration, peripheral edema, hypokalemia, 
hyperuricemia, hyperglycemia, hypocalcemia, hyponatremia 
Musculoskeletal 
Back pain, Arthalgia, bone pain, pain in extremities 
Respiratory 
Cough dysponea, upper respiratory tract infection, sinusitis, pneumonia, and 
wheezing, pulmonary fibrosis. 
Miscellaneous 
Chills, herpes zoster, chest pain, febrile neutropenia, infection, herpes 
simplex, myelodysplastic syndrome, sepsis, tumor lysis syndrome 
OVERDOSE 
Symptoms 
ECG changes, including QT prolongation, sinus tachycardia, ST- and T-
wave deviations, and left anterior fascicular block. 
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No specific antidote for TREANDA overdose is known. Management of over 
dosage should include general supportive measures, including monitoring of 
hematologic parameters and ECGs.  
5.2 EXCIPIENTS PROFILE 40 
 Substances, other than the active ingredient, which have been appropriately 
evaluated for safety and are included in a drug delivery system to provide support.  
 The excipients used must have following characteristics-  
1. They must be stable both physically, chemically and must be 
biologically inactive.   
2. It must be free from microbial contamination  
3. Excipients used in formulation must be accepted by regulatory 
agencies and should meet the entire current regulatory requirement. 
 The literature review of the innovator drug provided the qualitative and 
quantitative composition of the product. So, the same excipients (Mannitol) and 
solvents  (Tertiary  butyl  alcohol,  Water  for  Injection)  which  were  present  in  the  
innovator product were selected for the present study. 
5.2.1  Mannitol 
a)  Nonproprietary Names 
BP: Mannitol 
IP: D-Mannitol 
PhEur: Mannitol 
USP: Mannitol 
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b) Synonyms 
 Cordycepic acid, C*PharmMannidex, E421, Emprove; mannasugar, D-
mannite, mannite, mannitolum, Mannogem, Pearlitol 
c)  Chemical Name and CAS Registry Number 
 D-Mannitol [69-65-8] 
d)  Empirical Formula 
 C6 H14O6 
e)  Molecular Weight 
 182.17 
f) Functional Categories 
 Diluents, plasticizer, sweetening agent, tablet and capsule diluents, 
therapeutic agent, tonicity agent 
g) Applications in Pharmaceutical Formulation or Technology 
 Mannitol is widely used as a diluent (10–90% w/w) in tablet formulations, 
since it is not hygroscopic and may thus be used with moisture sensitive active 
ingredients. It may be used in direct compression tablet applications, for which the 
granular  and  spray  dried  forms  are  available,  or  in  wet  granulations.  Granulations  
containing Mannitol have the advantage of being dried easily.  
 It is also used as an excipient in the manufacture of chewable tablet 
formulations  because  of  its  negative  heat  of  solution,  sweetness,  and  ‘mouth  feel’  
and also used as a diluent in rapidly dispersing oral dosage forms 
 In lyophilized preparations, Mannitol (20–90% w/w) has been included as a 
carrier to produce a stiff, homogeneous cake that improves the appearance of the 
lyophilized plug in a vial.  A pyrogen-free form is available specifically for this use. 
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 It has also been used to prevent thickening in aqueous antacid suspensions 
of aluminum hydroxide (<7% w/v), and has been suggested as a plasticizer in soft-
gelatin capsules, as a component of sustained-release tablet formulations and as a 
carrier in dry powder inhalers. 
 Therapeutically, Mannitol administered parenterally is used as an osmotic 
diuretic, as a diagnostic agent for kidney function, as an adjunct in the treatment of 
acute renal failure, and as an agent to reduce intracranial pressure, treat cerebral 
edema, and reduce  intraocular pressure.  
h) Description 
 It occurs as a white, odorless, crystalline powder, or free flowing granules. 
It has a sweet taste and imparts a cooling sensation in the mouth. Microscopically, it 
appears as orthorhombic needles when crystallized from alcohol. 
i) Incompatibilities 
 Mannitol solutions, 20% w/v or stronger, may be salted out by potassium 
chloride or sodium chloride. Precipitation has been reported to occur when a 25% 
w/v solution was allowed to contact plastic.  
 It is incompatible with xylitol infusion and may form complexes with some 
metals such as aluminum, copper, and iron. Reducing sugar impurities in it have 
been implicated in the oxidative degradation of a peptide in a lyophilized formation.  
It was found to reduce the oral bioavailability of cimetidine compared to sucrose. 
j) Stability and Storage Conditions 
 It  is  stable  in  the  dry  state  and  in  aqueous  solutions.  In  solution,  it  is  not  
attacked by cold, dilute acids or alkalis or by atmospheric oxygen in the absence of 
catalysts. It does not undergo Mallard reactions. 
 The bulk material should be stored in a well-closed container in a cool, dry 
place. 
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5.2.2 TBA (Tertiary Butyl Alcohol) 
a) Empirical Formula : C4 H10O 
b) CAS no:   75-65-0  
c) Molecular Weight: 74.12 
d) Physical State and Color: Colorless liquid which forms rhombic-
like crystals 
e) Melting Point: 25.6 °C- 25.7 °C 
f) Boiling Point:  82.41 °C 
g) Specific Gravity: 0.78086 
h) Vapor Pressure: 30.6 mm Hg @ 20 °C; 42 mm Hg @ 25 °C 
i) Solubility: Soluble in water. 
j)  Flash point: 110 °C 
k) Explosion limits: 2.4 - 8% 
l) Stability 
 Stable. Very flammable Incompatible with strong oxidizing agents, copper, 
alloys, alkali metals, aluminium.  
 m) Toxicology 
 Harmful if inhaled. Skin and respiratory irritant, Severe eye irritant, Typical 
TLV (Threshold Limit Value) /TWA (time weighted average) - 100 ppm. Typical 
STEL (short term exposure limit) -150 ppm 
 n) Residual solvent limit in lyophilized product  
  NMT 3000 ppm 
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6.MATERIALS AND METHODS 
 
6.1  LIST OF METERIALS 
 
Table 4List of Raw Materials and Their Source 
S.No INGREDIENT VENDOR 
1 Bendamustine Hydrochloride NatcoPharma 
2 Mannitol 25 Roquette 
3 Tertiary butyl Alcohol Merck 
4 Water For Injection (WFI) NatcoPharma 
 
Table 5 List of Packaging Materials and Their Source 
S.No 
PRIMARY PACKING 
MATERIAL 
GRADE VENDOR 
1 50ml Glass Vials – USP Type – I USP MatriMirra 
2 20 mm Double slotted 
Bromobutylrubber stoppers 
USP/EP West 
Pharmaceuticals 
3 Aluminium flip off seals 
 
IH HBR Packaging 
India 
 
  
39 
 
Table 6List ofEquipments 
S.No 
NAME OF THE 
EQUIPMENT 
MANUFACTURER USE OF EQUIPMENT 
1 Lyophilizer LSI(lyophilization 
systems India pvt ltd) 
and Lyolab 
To perform the process of 
Freeze drying 
2 Weighing balance Mettler Toledo To weigh the raw materials 
and finished product 
 
3 pH meter Lab India PICO+ To find out the pH of the 
product before and after 
Lyophilization 
4 DO meter HACH Ultra To find the dissolved 
oxygen content of the 
solution 
5 Filtration unit Millipore 
 
To clarify the drug solution 
6 Osmometer 
 
Advanced 
instruments, INC 
3250 
To determine the osmolality 
of solution. 
7 HPLC Waters 2487 To know the assay and 
related substances of the 
drug. 
8 KF titrator MettlerToledo,DL50 
GRAPHIX 
To determine the water 
content of lyophilized drug 
9 Stability chambers Thermo-lab To conduct the stability 
studies of the drug product 
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Table 7List of Chemicals and Reagents used for HPLC 
S.No Reagents Grade Manufacturer 
1 Trifluoroacetic acid HPLC grade Merck 
2 Acetonitrile HPLC grade Merck 
3 Methanol HPLC grade Merck 
4 Potassium 
dihydrogenorthophosphate 
GR-grade Merck 
5 Triethyl amine HPLC grade Merck 
6 Methanol HPLC grade Merck 
7 Isopropyl Alcohol HPLC grade Merck 
 
6.2 PREFORMULATION STUDIES 
 Preformulation studies are performed to investigate the physical and 
chemical properties of a drug substance alone and also when combined with other 
substances such as excipients. It is the first step in the rational development of 
dosage forms.  
 The overall objective of performing preformulation testing is to generate 
information that will be helpful in developing a stable and bioavailable dosage form 
when combined with excipients.  
 The use of Preformulation parameters maximizes the chances in 
formulating an acceptable, safe, efficacious and stable product and at same time 
provides the basis for optimization of the drug product quality. 
6.2.1 Preparation of Standard Graph 
 Bendamustine Hydrochloride (20.0mg) working standard was accurately 
weighed and transferred into 200 mL amber colored volumetric flask. To this 60 ml 
of methanol was added, it was dissolved and the volume was made up to the mark 
with methanol. Followed by serial dilution method, the concentrations of 5, 10, 20, 
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40, 80,160(mcg/ml) of Bendamustine Hydrochloride was analyzed by HPLC at 
wave length of 275nm and the peak areas were noted.  A standard graph of the peak 
areas versus the concentration of the drug was plotted. 
6.2.2 Organoleptic Properties 
 The color, odour and taste of the drug were recorded using descriptive 
terminology. 
6.2.3 Saturation Solubility Studies 
a)  In water 
 It was determined by adding excess Bendamustine Hydrochloride in a fixed 
volume (10ml) of water. It was kept under shaking for 24hrs on a shaker. It is 
further filtered and analyzed using HPLC at 275nm. 
b)  In water and alcohol  
 The solubility of bendamustine hydrochloride in water and with varying 
amounts of alcohols commonly used in lyophilization. 
E.g.: methanol,ethanol,propanol,butanol, and TBA (territory butyl alcohol) was 
determine by visual inspection. 
 Amount of bendamustine hydrochloride at 15 mg/ml, combined with 
mannitol at 25.5 mg/ml were prepared in 10 ml of the individual alcohol solutions at 
room temperature. Sample ware then refrigerated at 5o C and inspected after 0, 
3,6,24 hrs for particulates and/or precipitates 
6.2.4 Solution Stability Studies 
 The stability studies in TBA were carried out as follows: 
 WFI (100ml) was taken in a beaker. To this required quantity of TBA, 
Mannitol&Bendamustine Hydrochloride was added and is dissolved by stirring. The 
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volume is made up to 200ml with WFI. This preparation was divided into 8 lots 
from which 4 lots were stored at 250C, while remaining 4 lots were stored at 2 - 80C 
for 24 hours. Further analysis was performed after each interval i.e. 3,6,9,12,24 hrs. 
Table 8 TBA stability studies at different level of temperatures  
(250C and at 2-8 0C) 
S.No Ingredient 
TBA 10% TBA 20% TBA 30% TBA 40% 
Qt/ml Qt/200ml Qt/ml Qt/200ml Qt/ml Qt/200ml Qt/ml Qt/200ml 
1 B.H 5mg 1gm 5mg 1gm 5mg 1gm 5mg 1gm 
2 Mannitol 6mg 1.2gm 6mg 1.2gm 6mg 1.2gm 6mg 1.2gm 
3 TBA 0.1ml 20ml 0.2ml 40ml 0.3ml 60ml 0.4ml 80ml 
4 WFI q.s q.s q.s q.s q.s q.s q.s q.s 
 
B.H=Bendamustine Hydrochloride, WFI=Water for injection, TBA = tertiary 
butyl alcohol, q.s=quantity sufficient 
6.3 FORMULATIONOFBENDAMUSTINE 
HYDROCHLORIDEINJECTION 
Table 9 manufacturing formula 
S.No Ingredients Category 
1 Bendamustinehydrochloride Active ingredient 
2 Mannitol Lyophilization aid 
3 Tertiary butyl alcohol Solvent 
4 Water for injection (WFI) Diluent 
 
6.4 FORMULATION OF BENDAMUSTINE HYDROCHLORIDE 
 Different formulations of pre-lyophilized bendamustine hydrochloride 
injection were prepared with different solvent concentration of TBA and WFI. The 
formulation were shown in table 11.the cycle development was changed and 
optimized at each step for freezing (fast Vsslow), primary drying (both temperature 
and pressure) and secondary drying. 
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Table 10Formulation of Bendamustine Hydrochloride 
S.no Ingredients FI FII FIII FIV 
1 B.H (gm) 1 1 1 1 
2 Mannitol (gm) 1.2 1.2 1.2 1.2 
3 TBA (ml) - 40 60 80 
4 WFI 200 160 140 120 
 
B.H=Bendamustine Hydrochloride, WFI=Water for injection, TBA = Tertiary 
Butyl Alcohol 
Table 11 formulafor single vial 
S.No Ingredients Qt/ml Qt/vial (20 ml) 
1 Bendamustine hydrochloride 5mg 100 mg 
2 Mannitol 6 mg 120 mg 
3 Tertiary butyl alcohol 0.3 ml 6 ml 
4 Water for injection q.s q.s 
 
Manufacturing procedure 
1. About 50% of WFI (water for injection) was taken in a beaker and 
cooled at 250 C. To this dispensed quantity of TBA (tertiary butyl 
alcohol) was added and mixed well until homogeneous solution is 
obtained. This solution was cooled to 2-80C .The pH of the solution was 
found to be 6.8.  
2. Weighed quantity of Mannitol was added to the above solution and 
dissolved by stirring at a speed of 200 RPM under 2-8 0Ccondition until 
clear solution was observed.  
3. Weighed quantity of Bendamustine Hydrochloride was added and 
dissolved by stirring for 30 minutes at a speed of 200 RPM under 2-80C 
condition. The pH of the solution was found to be 3.1 
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4. The solution was then made up to the volume 200 ml with WFI under 2-
8oC condition. The final pH of the solution was found to be 3.1  
5. The final solution was filtered using 0.22-µm PVDF (poly vinyl 
disposable filter). 
6. The solution was filled  into 50 ml of amber colored USP-Type-1 vial 
with target fill volume of 20 ml with pre and post purging of Nitrogen 
half stoppered, the vials with 20mm Lyophilized stoppers 
7. Filled vials are loaded into the lyophilizer and lyophilized the vials as 
per cycle conditions mentioned in Table 15 (Set the shelf temperature 
prior to cycle staring to 5oc) 
8. The  samples  are  collected  after  the  completion  of  the  cycle.  The  
samples are withdrawn under the nitrogen atmospheric conditions after 
the atmospheric pressure is reached, stoppered and sealed. The vials are 
unloaded from the lyophilizer and sealed using flip off aluminum seals 
&Lyophilized vials are stored at room temperature. 
 
6.5 COMPATIBILITY STUDIES WITH PROCESS COMPONENTS 
Definition: Compatibility is a measurement of how stable a substance is when it is 
in contact with another material. If there is no change in the physical and chemical 
properties of the substance when it is in contact with other materials, then it is 
considered as compatible. If changes occur, then it is considered as incompatible. 
Types of Compatibility Studies: 
1. Filter compatibility 
2. Silicone Tubing compatibility 
3. SS Vessel compatibility  
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6.5.1  Filter Compatibility Study 
x Filter material must be compatible with the chemical nature of the 
sample  stream  under  the  conditions  at  which  the  filtration  will  be  
performed. This will minimize the risk of structural failure during 
filtration. 
x The purpose of this study was to determine the effect of stability on 
prolonged exposure of filter membrane to drug product. 
a) Study Design: 
 This study can be done in two ways. 
a) Static Soak Method: 
 In this study, the test filter shall be soaked in the drug product solution for 
longer period. 
b) Dynamic Filtration: 
 In this study, the liquid is continuously circulated through the filter 
membrane repeatedly. 
 Of these both methods, static soak method was used for the present study. 
6.5.1.1  Experimental procedure 
x The test filter (PVDF filter) shall be subjected to autoclaving and 
then use it for the compatibility studies. 
x Place the filter membrane in drug product solution and keep aside at 
2-8ºC. 
x At regular time intervals (0, 2, 4, 6 hours) withdraw the required 
amount of sample and perform analysis of it. 
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6.5.2  Silicone Tubing Compatibility Study 
• Silicone tubing’s are commonly used as processing aid during 
filtration and filling operation for transfer of liquid in pharmaceutical 
manufacturing. They are known to adsorb or interact with product and 
may lead to instability of product. 
• The purpose of this study was to determine the effect of silicone 
tubing exposure on drug product characteristics. 
• In the present study Pharma Pure silicon tubing was used. 
a) Study Design: This study shall be planned in two ways. 
b) Static Condition: In this case the liquid is hold in the tube for longer 
period. 
c) Dynamic Condition: In this case the liquid is continuously passed from 
the tubing at a constant flow rate for required time period.  
 Of these both conditions, static method was used for the present study. 
6.5.2.1  Experimental procedure 
x Collect the required length of tubes and check the tubes physically for 
any damage 
x Wash the tubes using potable water followed by WFI and wrap in 
autoclavable pouch and sterilize at 121°C for 30 minutes. 
x Open the tube under laminar air flow and check for any damage after 
sterilization and then fill the tube with drug product solution.  
x Close the both ends of tube and kept at 2-8°C. 
x At regular time intervals (0, 2, 4, 6 hours) withdraw the required 
amount of sample and perform analysis of it. 
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6.5.3  SS Vessel Compatibility Study 
• SS vessels  are  commonly  used  in  fabrication,  filtration  and  filling  of  
drug products. During this hold period the drug product may interact 
with SS 316 vessel and this may lead to incompatibility. 
• The compatibility study with SS vessel is required to establish holding 
period. 
6.5.3.1  Experimental procedure 
x Collect the SS 316 vessel. Wash it and sterilize at 121°C for 30 min. 
x Fill the drug solution into the SS vessel after its filtration and then 
close the container. 
x At regular time intervals (0, 2, 4, 6 hours) withdraw the required 
amount of sample and perform analysis of it. 
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6.6 LYOPHILISATION CYCLE DEVOLOPMENT 
Table 12 Different lyophilization conditions with varying temperature and duration of cycle 
S.no  F 1 F 2 F 3 F 4 
  T 1 T 2 T 3 T 1 T 2 T 3 T 1 T 2 T 3 T 1 T 2 T 3 
1 FREEZING             
 Rate of freezing Fast Fast Fast Fast Slow Slow Fast Slow Slow Fast Slow Slow 
 Duration (hrs) 4.5 6.5 7.58 7.58 23.25 18.8 7.58 23.25 18.8 7.58 23.3 18.8 
 Final freezing 
temperature (qC) 
-40 -45 -45 -40 -45 -45 -40 -45 -45 -40 -45 -45 
 Annealing step No No No No Yes Yes No Yes Yes No Yes Yes 
2 PRIMARY DRYING              
 Duration (hrs) 19 27 43.5 29 32.16 53 29 32.16 53 29 35.6 53 
 Final shelf 
temperature (qC)  
40 40 40 30 35 35 30 35 35 30 35 35 
3 SECONDARY 
DRYING  
            
 Duration (hrs) 2 8.5 8 11 14.1 14.1 11 14.1 14.1 11 16 14.1 
 Final shelf 
temperature(qC) 
40 40 40 35 35 40 35 35 40 35 35 40 
 Entire cycle duration 
(hrs) 
25.5 42 59.08 47.58 69.5 85.9 47.5 69.5 85.9 47.5 69.5 85.9 
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6.7 EVALUATION OF LYOPHILIZED PRODUCT 
 The lyophilized product was evaluated for the following formulation 
characteristics: 
x Description 
x Reconstitution time 
x Clarity of reconstituted solution. 
x pH after reconstitution 
x Water content 
x Assay 
x Related substances 
x Diluent compatibility studies. 
x Stability studies as per ICH guidelines 
x Photo stability studies. 
6.7.1  Description 
 It involves the physical examination of the sample after lyophilization. 
6.7.2  Reconstitution Time 
 Vial was reconstituted (100mg – 20 ml) with water for Injection. 
 Water for injection was slowly injected directing the syringe tip onto the 
wall of the vial. 
 The  vial  was  gently  shaken  by  tilting  the  vial  upside  down until  the  cake  
dissolves and the  Timewas noted till it completely dissolves and this was called as 
Reconstitution time. 
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 The final solution was preserved for the test clarity and color of the 
solution. 
6.7.3  Clarity of Reconstituted Solution 
 The above preserved solution in the test for “Reconstitution time” was 
transferred  into  a  clear  test  tube  and  the  clarity  and  color  of  the  solution  was  
observed. 
 The  solution  should  be  clear  colorless  leaving  no  visible  residue  as  
undissolved matter. 
6.7.4 pHafter Reconstitution 
 The vials were reconstituted with carbon-dioxide free water and thenthe pH 
of the solution was measured using a suitable calibrated pH meter. 
6.7.5 Water Content 
 The amount of water present in the lyophilized drug was determined using 
Karl Fisher Titrimetry method. 
Procedure 
 Methanol (20ml) was taken into the titration vessel and titrated the 
amperometric  end  point  with  Karl  Fischer  Reagent.  To  this  0.1  gm  of  the  sample  
was added, it is stirred for 1 minute and again titrated to the amperometric end point 
with Karl Fischer Reagent.  
(܂.܄× ۹.۴. ۴ۯ۱܂۽܀ × ૚૙૙)
܅ܜܗ܎ܛ܉ܕܘܔ܍ × ૚૙૙  
*T.V=Titrevalue,K.F=Karl fischer 
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6.7.6  Assay 
 Assay was done to find and measure the amount of drug in the final 
product. 
 In the present study, HPLC method was used to determine the assay. 
Preparation of Buffer 
 Potassium dihydrogen orthophosphate (6.8) was dissolved in 1000 mL of 
purified water, the pH was adjusted to 7.0 ±0.1 with Triethylamine. The solution 
was mixed, filtered through 0.45ߤ݉membrane filter and degas. 
Preparation of Mobile phase 
 The Buffer and Methanol mixture was prepared in the ratio of 370:630 v/v, 
filtered through 0.45ߤm membrane filter and degas. 
Diluent 
 Methanol was used as diluent. 
Table 13Chromatographic conditions 
Column Develosil, ODS UG-5, (150  4.6mm) 
Flow rate 0.8 mL / minute 
Wavelength UV-275 nm 
Column temperature 30  
Sample temperature 5  
Injection Volume 10  
Run time 12 minutes 
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Preparation of sample solution 
 5  vials  were  taken  and  they  are  reconstituted  with  40  mL  of  diluent,  
without  any  loss  of  solution  and  these  are  transferred  into  500  mL  amber  colored  
volumetric flask.The vials were washed with 10 mL of diluents for 2 -3 times and 
the volume was made up to 500 mL with diluents and mixed well. 
 2.0  mL of  the  above  solution  was  transferred  into  100  mL amber  colored  
volumetric flask, and the volume was made up with the diluents. 
Procedure 
 10ߤL of diluent as blank, standard preparation, sample preparations are 
separately injected into the chromatograph, the peak area responses are measured 
from the obtained chromatograms. The % content of Bendamustine Hydrochloride 
in the portion of Bendamustine Hydrochloride injection was calculated by using the 
formula 
% Content of Bendamustine (mg/vial)                 
ܶܣ
ܵܣ
× ܹܵ200 × 525 × 5005 × 1002 × ܲ100 × 100ܮܣ  
Where, 
 TA:   peak area response due to Bendamustine Hydrochloride from sample 
preparation. 
 SA:   peak area response due to Bendamustine Hydrochloride from 
standard preparation. 
 SW:  Weight of Bendamustine Hydrochloride working standard taken in 
mg. 
 P:  purity of Bendamustine Hydrochloride working standard taken on as 
is basis. 
 LA:  Label Amount in mg. 
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6.7.7 Related Substances 
 Related substances are the unwanted substances or the degradants which 
may be present in the final product along with the drug substance. Thus they form 
the impurity of the drug product.  So these are to be found out and the total impurity 
has to be calculated. 
 HPLC method was used to determine the amount of related substances.  
a)  Preparation of Mobile phase -A 
  1.0 mL of TrifluoroaceticAcidwas mixed in 1000mL of water, filtered 
through 0.45 ߤm membrane filter and degas. 
b)  Preparation of Mobile phase – B 
 1.0 mL of Trifluoroacetic Acid was mixed in 500mL of water, to this 
500mL Acetonitrile was added, filtered through 0.45 ߤm membrane filter and degas. 
c)  Diluent 
 Methanol was used as diluent. 
Table 14Chromatographic conditions 
Column Develosil, UG-5, C-18 (250  4.6mm) 
Flow rate 0.8 mL / minute 
Wavelength UV-275 nm 
Column temperature 30  
Sample temperature 5  
Injection Volume 15  
Run time 15 minutes 
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Table 15Gradient programming 
Time(min) Flow(mL/min) 
Mobile phase-A 
(% v/v) 
Mobile phase-B 
(% v/v) 
0 0.8 75 25 
2 0.8 75 25 
10 0.8 60 40 
18 0.8 60 40 
25 0.8 20 80 
35 0.8 20 80 
39 0.8 15 85 
PREPARATION OF SOLUTIONS 
a)  Preparation of standard solution 
 Accurately weigh and transfer about 20.0 mg of Bendamustine 
Hydrochloride working standard into a 200-mL amber colored volumetric flask. 
Add about 120 mL of diluents and sonicate to dissolve then make up to the volume 
with diluents and mix well. 
 Transfer 1.0 ml of the above solution into a 200 mL amber colored 
volumetric flask, dilute to volume with diluents 
b)  Peak identification solution preparation 
 Accurately weigh and transfer about each 5.0 mg of Dihyroxy Impurity, 
Monochloro impurity, Monohydroxy Impurity, BND-VI Impurity, IPA Ester 
Impurity and Bendamustine Hydrochloride working standard into 100 mL amber 
colored volumetric flask and add 60mL diluent, sonicate to dissolve and dilute to 
volume with diluents. 
 Transfer 2.0 mL of the above solution into a100 mL amber colored 
volumetric flask and dilute to volume with diluent. 
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c)  Preparation of sample solution (For Bendamustine Hydrochloride 
Injection 100mg/vial) 
 Take 2 vials and reconstitute each vial with 10mL of diluents, dissolve and 
transfer the contents into 200 mL amber colored volumetric flask without any loss 
of solution. Wash the vials with 10 mL of diluents for 2-3 times and make upto the 
volume to 200 mL with diluents, shake and mix well. 
Transfer 10.0 mL of the above solution into a 20 mL volumetric flask, dilute to 
volume with diluents 
d)  Procedure 
 15ȝL  of diluents as blank, placebo, peak identification solution, standard 
preparation and sample preparations are injected into the chromatograph, the peak 
area responses are measured from the obtained chromatograms. The % content of 
Bendamustine Hydrochloride in the portion of Bendamustine Hydrochloride 
injection was calculated by using formula. 
Table 16 RRT and RRF of different components 
Component Name 
Relative Retention Time 
(RRT) 
Relative Retention Factor 
(RRF) 
Bendamustine About 1.00 1.00 
Dihydroxy Impurity About 0.20 0.28 
Monochloro Impurity About 0.59 0.53 
Monohydroxy Impurity About 0.63 0.88 
BND-VI impurity About 0.46 0.74 
IPA Ester Impurity About 1.41 0.81 
 
Calculations (For Bendamustine Hydrochloride Injection 100mg/vial)% of 
Known impurities 
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ܫܣ
ܵܣ
× ܹܵ200 × 1200 × 2002 × 2010 × ܲ100 × 1ܮܣ × 100ܴܴܨ 
% of Unknown impurities 
ܫܣ
ܵܣ
× ܹܵ200 × 1200 × 2002 × 2010 × ܲ100 × 1ܮܣ × 100 
Total Impurities 
 Sum of Known impurities + Unknown impurities 
UA  : Peak area response due to Un-Known impurity from sample preparation. 
SA   : Peak area response due to Bendamustine Hydrochloride from standard 
preparation.  
WS   :  Weight of Bendamustine Hydrochloride working standard taken in mg. 
P     : purity of Bendamustine Hydrochloride working standard taken on as is 
basis. 
LA     :  Label Amount of Bendamustine Hydrochloride. 
RRF   :  Relative Response Factor of respective known impurity. 
IA     :   Peak area response due to Known impurity from sample preparation 
6.8 DILUENT COMPATIBILITY STUDIES 
OBJECTIVE 
 This study aims to establish the compatibility of Bendamustine 
Hydrochloride lyophilized product with diluents such as 0.9% Sodium Chloride 
Injection, USP or 2.5% Dextrose injection/0.45 Sodium chloride injection, USP 
which are recommended for dilution in the package insert of innovator for the 
recommended duration. 
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a)  Procedure: 
 The powder was immediately reconstituted after opening of the vial 
(100mg) with 40 ml of water for injection (WFI). The reconstituted concentrate is 
diluted immediately with 0.9% NaCl solution (500ml). 
 After reconstitution and dilution chemical and physical stability has been 
demonstrated for 3.5hrs at 250C and for 48 hrs at 2-80C in polyethylene bags. 
The various test parameters that are evaluated include: 
x Description 
x pH 
x Assay 
x Related substances 
x Osmolality 
Table 17 Acceptance criteria 
S.No TEST PARAMETER LIMITS 
1 Description Clear, Colorless solution. 
2 PH Between 2.5-3.5 
3 Assay (%) 90 – 110 
4 Related substances (%) NMT  3 
5 Osmolality (m.osm) 290- 310 
 
B)  Osmolality 
 The powder was immediately reconstituted after opening of the vial 
(100mg) with 40 ml of water for injection (WFI). The reconstituted concentrate is 
diluted immediately with 0.9% NaCl solution (500ml).  From this 0.2ml of solution 
is taken in holder and kept in osmometer and freezed for 90 sec the reading is noted. 
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6.9 INNOVATOR DETAILS 
 The innovator drug product information can be collected from various 
sources such as:  
(i) USFDA,  EMEA,  WHO,  etc.  –  for  the  composition  and  primary  
package of innovator product. 
(ii) Patent search – for existence or expiration of the patents. 
(iii) IIG – for the excipients information. 
(iv) Publicly available information (PIL, Product Monographs, Label 
information, Consumer information, etc.) 
(v) Pharmacopoeias – United States Pharmacopoeia-National Formulary 
(USP-NF), British Pharmacopoeia (BP), European Pharmacopoeia, 
etc. 
(vi) Martindale, Merck index, PDR, Handbook of the excipients and 
electronic data base (articles and publications) – for the other 
required information like solubility data, stability data, pH solubility 
& stability data, compatibility data, etc. 
Marketed brand of bendamustine hydrochloride  
 
 
 
 
Figure 7 Innovator product “TREANDA” 
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Label contains  
 Vial with 220 mg of powder for infusion solution containing 100 mg of 
Bendamustine Hydrochloride, main inactive ingredient is Mannitol 
Table 18 
Name of the product Treanda 
Manufacturer name Cephalon 
 Color White to off white 
Description Lyophilized cake 
Package 50ml amber colored USP-Type-1 vial 
 
6.10 STABILITY STUDIES AS PER ICH GUIDELINES41 
 Stability is defined as the capacity of drug product or substance to remain 
within established specifications to maintain its identity, strength, quality and purity 
throughout the retest or expiration dating periods. 
 Stability studies provide an evidence on how the quality of the drug 
product or substance varies with time under the influence of a variety of 
environmental factors such as  
• Temperature 
• Humidity 
• Light 
These studies establish the 
• Re-test period of the drug product 
• Shelf life for the drug product 
• Recommended storage conditions 
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 In any rationale design and evaluation of dosage forms for drugs, the 
stability of the active component will be major criteria in determining their 
acceptance or rejection. So, in the  
 Present study, the stability of the drug product is assessed by exposing the 
product to various temperatures and humidity conditions. 
a) Accelerated study: The product was subjected to accelerated stability 
studies at 40qC±2qC/75% ±5% RH for 6 months. The frequency of testing 
at the Accelerated study condition includes 0, 1, 2, 3, 6 months. 
b) Long term study:  The  product  was  subjected  to  long  term  studies  at  
25qC±2qC/60% ±5%RH for 12 months. The frequency of testing at the 
long term storage condition is for every 3 months over the first year, every 
6 months over the second year. Thesampling withdrawn schedule was 
illustrated in the table below. 
Table 19 stability sampling withdrawal schedule 
S.NO. STORAGE CONDITION TEST PERIOD 
1 
40qC±2qC/75% ±5% RH 
1 month 
2 month 
3 month 
2 25qC±2qC/60% ±5% RH 3 month 
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Table 20 shelf life specifications for compliance during stability 
                 TESTS                                 SPECIFICATIONS 
 
Description 
 
White to Off-white lyophilized cake or powder 
in a tubular50ml clear USP Type - I glass vial 
sealed with bromobutyl double slotted rubber 
stopper and aluminum flip-off seal. 
pH after reconstitution 2.50 to 3.50 
Reconstitution time  NMT  5 
Clarity of reconstituted solution 
 
 
 
The solid dissolves completely leaving no visible 
residue as undissolved matter. 
Reconstituted solution should not be 
significantly less clear than an equal volume of 
the diluent  
 
Assay (%)  90-110 
Related substances (%) NMT  3 
Osmolality (m.osm) 290 to 310  
Water content by KF (%w/w) NMT  3 
 
6.11 PHOTOSTABILITY STUDY42 
OBJECTIVE 
• This study aims to evaluate the stability of the drug product when 
exposed to light.  
• The intrinsic photostability characteristics of the drug product should 
be evaluated to demonstrate that, as appropriate, light exposure does 
not result in an unacceptable change.  
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STUDY PLAN 
Instructions 
x The temperature of the photo stability chamber should be maintained 
at 25°C ± 2°C during the study. 
x Vials shall be delabelled for the study. Though the immediate and 
marketing pack includes the label, in the current study, labels are 
being removed to study the photo stability characteristics of the 
product under maximum light stress. 
x Samples should be placed horizontally or transversely with respect to 
the light source, whichever provides maximum light exposure to the 
samples.  
x Check and ensure that photo stability chamber is duly calibrated 
before use. 
Table 21various samples for photo stability studies 
SAMPLE DESCRIPTION 
NUMBER 
OF VIALS 
Sample 1 
(Product in immediate pack) 
Delabelled product vials 20 vials 
Sample 2 
(Product in marketing pack) 
Delabelled product vials placed in 
cartons 
20 vials 
Temperature/Dark Control 
Sample 
Delabelled product vials wrapped 
with Aluminium foil 
20 vials 
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Sample 1: 
 Collect specified number of vials and place them horizontal to the light 
source. 
Sample 2: 
 Collect the specified number of vials and place them in opaque white 
cardboard cartons. The cartons shall be placed in a manner such that the vials placed 
inside remain in a horizontalcondition. Though no light exposure is expected in 
these samples, the placement of samples is simulated as closely as possible to the 
“Sample 1” vials. 
Temperature/Dark Control Sample:   
 Collect the specified number of vials and wrap them thoroughly with 
aluminium foil leaving no exposed surfaces. Place these vials alongside the “Sample 
1” vials in horizontal condition simulating the placement of the “Sample 1” vials. 
The dark control samples shall be evaluated to understand the contribution of 
thermally induced changes in the “Sample 1” and “Sample 2” product vials 
PROCEDURE 
• All the samples shall be exposed to light providing an overall 
illumination of not less than 1.2 million lux hours and an integrated 
near ultraviolet energy of not less than 200 watt hours/square meter.  
• At the end of the exposure period, the product samples should be 
examined for the parameters listed below. The analysis of “Sample 
1”, “Sample 2” and the temperature or dark control samples shall be 
performed concomitantly. 
 The various test parameters which were evaluated during this study 
included: 
 64 
 
Table 22 Acceptance criteria 
          TESTS                  SPECIFICATIONS 
Description White to off-white lyophilized cake or 
powder. 
pH after reconstitution 2.50 to 3.50 
Reconstitution time NMT  5 min 
Clarity of reconstituted 
solution 
 
The solid dissolves completely leaving no 
visible residue as undissolved matter. 
Reconstituted solution should not be 
significantly less clear than an equal volume 
of the diluent  
Assay (%)  90-110 
Related substances (%) NMT  3 
Water content by KF (%w/w) NMT3 
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7. RESULTS 
 
7.1  PREFORMULATION STUDYS 
7.1.1 Standard Graph of Bendamustine Hydrochloride 
 The concentrations of Bendamustine Hydrochloride and the corresponding 
peak area values are shown in the Table 23 .The plot of concentration versus peak 
area is shown in the Figure 9. 
Table 23Standard graph data of Bendamustine Hydrochloride 
S. No. Concentration(mcg/ml) Peak Area at 275 nm 
1 0 0 
2 5 243310 
3 10 546620 
4 20 1093240 
5 40 2286480 
6 80 4172960 
7 160 8445920 
 
 
 
 
 
 
Figure 9Standard graph of Bendamustine Hydrochloride 
y = 52617x + 30602
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7.1.2 Description 
 The received sample of API after visual observation it was found to show 
the white to off-white color 
7.1.3 aturation Solubility Studies 
a)  In Water  
 The solubility of Bendamustine hydrochloride was found to be 60mg/ml 
b)  In Water and Alcohol 
Table 24  
S.No Substance 0hrs 3 hrs 6 hrs 24 hrs 
1 Water     
2 Methanol (v/v)     
 5% CCS CCS PPT PPT 
 10% CCS CCS PPT PPT 
 20% CCS CCS CCS PPT 
 30% CCS CCS CCS CCS 
3 Ethanol (v/v)     
 5% CCS CCS PPT PPT 
 10% CCS CCS CCS PPT 
 20% CCS CCS CCS CCS 
 30% CCS CCS CCS CCS 
4 n-propanol(v/v)     
 5% CCS CCS CCS PPT 
 10% CCS CCS CCS CCS 
 20% CCS CCS CCS CCS 
 30% CCS CCS CCS CCS 
5 Iso-propanol (v/v)     
 5% CCS PPT PPT PPT 
 10% CCS CCS CCS CCS 
 20% CCS CCS CCS CCS 
 30% CCS CCS CCS CCS 
6 n-butanol (v/v)     
 5% CCS CCS CCS CCS 
 10% CCS CCS CCS CCS 
 20% 2-layers 2-layers 2-layers 2-layers 
 30% 2-layers 2-layers 2-layers 2-layers 
7 TBA(v/v)     
 5% CCS CCS CCS PPT 
 10% CCS CCS CCS PPT 
 20% CCS CCS CCS CCS 
 30% CCS CCS CCS CCS 
*ccs= clear, colorless solution, Ppt=precipitate
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7.1.4 Solution Stability Studies 
Table 25 Solution Stability Studies of 10%, 20% TBAat250C 
S. 
No 
Parameters 
10% TBA Stored at 250C 20% TBAStored at250C 
Time (hours) Time (hours) 
0 3 6 9 12 24 0 3 6 9 12 24 
1 Description Clear Clear Clear Clear Clear Clear Clear Clear Clear Clear Clear Clear 
2 pH 2.8 2.6 2.5 2.5 2.3 2.3 2.9 2.8 2.7 2.5 2.5 2.2 
3 Assay (%) 104.7 97.6 89.2 85.6 80.2 76.3 104.6 100.5 99.4 95.7 93.1 88.9 
4 Related substance 
SingleMax(%) 1.87 10.01 16.67 20.08 22.54 30.32 1.37 5.42 8.71 10.9 12.3 18.49 
Total Imp (%) 2.04 10.96 19.12 23.58 27.01 39.6 1.51 5.93 9.70 12.3 14.0 22.0 
 
Table 26 Solution Stability Studies of 30%, 40% TBAat250C 
S. 
No Parameters 
30% TBA Stored at 250C 40% TBAstored at250C 
Time (hours) Time (hours) 
0 3 6 9 12 24 0 3 6 9 12 24 
1 Description Clear Clear Clear Clear Clear Clear Clear Clear Clear Clear Clear Clear 
2 pH 3.1 3.0 2.9 2.9 2.8 2.6 3.3 3.2 3.0 2.9 2.7 2.7 
3 Assay (%) 105.2 104 103.2 102.1 101.3 100 106 105 103 102 101.5 100 
4 Related substance 
Single Max(%) 0.93 2.47 3.15 3.87 4.66 6.86 0.95 1.56 3.12 3.98 4.75 6.50 
Total Imp (%) 1.05 2.71 3.48 4.29 5.17 7.73 1.12 2.77 3.48 4.79 5.67 7.57 
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Table 27 Solution Stability Studies of 10%, 20% TBA at 2-80C 
S. 
No Parameters 
10% TBAStored at 2 - 80C 20% TBAstored at2 - 80C 
Time (hours) Time (hours) 
0 3 6 12 18 24 0 3 6 12 18 24 
1 Description Clear Clear Clear Clear Clear Clear Clear Clear Clear Clear Clear Clear 
2 pH 2.7 2.6 2.5 2.5 2.3 2.3 2.9 2.8 2.7 2.6 2.6 2.4 
3 Assay (%) 102.7 98.4 92.8 87.6 84.2 81 104.2 103.2 101.8 100.5 99.6 94.2 
4 Related substance 
Single Max(%) 1.26 1.94 2.85 4.62 6.23 8.71 0.10 0.27 0.64 0.97 1.27 1.94 
Total Imp (%) 1.48 2.12 3.02 5.21 6.81 9.68 0.24 0.59 1.15 1.54 1.98 2.58 
 
Table 28Solution Stability Studies of 30%, 40% TBA at 2-80C 
S. 
No 
Parameters 30% TBAStored at 2 - 80C 40% TBAstored at2 - 80C 
Time (hours) Time (hours) 
0 3 6 12 18 24 0 3 6 12 18 24 
1 Description Clear Clear Clear Clear Clear Clear Clear Clear Clear Clear Clear Clear 
2 Ph 3.066 3.064 3.05 3.04 3.022 3.019 3.19 3.19 3.19 3,18 3.18 3.18 
3 Assay (%) 105.2 104 103.2 102.1 101.3 100 99.3 97.9 101.6 100.9 101.5 99.0 
4 Related substance 
Single Max(%) 0.16 0.18 0.20 0.27 0.29 0.68 0.18 0.24 0.28 0.48 0.64 0.94 
Total Imp (%) 0.23 0.24 0.50 0.59 0.71 0.80 0.26 0.59 0.61 0.72 1.12 1.62 
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7.2  COMPATIBILITY STUDY RESUTS  
Table 29PVDF Filter Compatibility Study 
S.no Test parameter Specification Initial 
PVDF Filter compatibility 
2hrs 4hrs 6hrs 
1 Description CCS CCS CCS CCS CCS 
2 Assay (%) 90-100 99.5 99.3 99.1 99.08 
3 pH after reconstitution 2.5-3.5 3.1 3.15 3.21 3.25 
4 Related substances      
 BND-IV impurity (%) 0.55 ND ND ND ND 
 Dihydroxy impurity (%) 0.5 ND ND ND ND 
 Monohydroxy impurity (%) 0.5 0.248 0.249 0.252 0.252 
 IPAester impurity (%) 0.5 0.042 0.042 0.043 0.045 
 Single max (%) 1.0 0.032 0.033 0.035 0.036 
 Total impurities (%) NTM 3 0.322 0.324 0.329 0.333 
 
*CCS=Clear Colorless Solution, ND=Not Detected, BEND-VI = Bendamustine, IPA = Isopropyl Acetate 
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Table 30Silicon Tubing Compatibility Study (Pharma Pure Silicon Tube) 
S.no Test parameter Specification Initial 
Pharma Pure compatibility               
(storage at 2-8 ºC) 
2hrs 4hrs 6hrs 
1 Description CCS CCS CCS CCS CCS 
2 Assay (%) 90-110 99.5 99.47 99.42 99.4 
3 pH after reconstitution 2.5-3.5 3.1 3.14 3.16 3.21 
4 Related substances      
 BND-IV impurity (%) 0.55 ND ND ND ND 
 Dihydroxy impurity (%) 0.5 ND ND ND ND 
 Monohydroxy impurity (%) 0.5 0.248 0.248 0.252 0.254 
 IPAester impurity (%) 0.5 0.042 0.046 0.050 0.052 
 Single max (%) 1.0 0.032 0.036 0.038 0.042 
 Total impurities (%) NTM 3 0.322 0.33 0.34 0.348 
 
 *CCS=Clear Colorless Solution, ND=Not Detected, BEND-VI = Bendamustine, IPA = Isopropyl Acetate 
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Table 31SS Vessel Compatibility Study 
S.no Test parameter Specification Initial 
SS Vessel compatibility 
(storage at 2-8 ºC) 
2hrs 4hrs 6hrs 
1 Description CCS CCS CCS CCS CCS 
2 Assay (%) 90-110 99.5 99.48 99.39 99.32 
3 pH after reconstitution 2.5-3.5 3.1 3.15 3.22 3.22 
4 Related substances      
 BND-IV impurity (%) 0.55 ND ND ND ND 
 Dihydroxy impurity (%) 0.5 ND ND ND ND 
 Monohydroxy impurity (%) 0.5 0.248 0.252 0.262 0.262 
 IPAester impurity (%) 0.5 0.042 0.048 0.058 0.058 
 Single max (%) 1.0 0.032 0.036 0.050 0.050 
 Total impurities (%) NTM 3 0.322 0.336 0.351 0.37 
 
 *CCS=Clear Colorless Solution, ND=Not Detected, BEND-VI = Bendamustine, IPA = Isopropyl Acetate
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7.3  FORMULATION RESULTS  
7.3.1  Lyophilization of F1 formulation 
Trail 1 
Table 32Freezing 
Controlled parameters 
Events 
1 2 3 4 
Shelf temperature (0C) -15 -15 -40 -40 
Time ( min) 30 60 60 120 
Final freeze temperature (0C) -40 
Duration of freezing (hours) 4.5 
 
Table 33PrimaryDrying 
Controlled 
parameters 
Events 
1 2 3 4 5 6 7 8 9 10 
Shelf temperature (0C) -30 -30 -20 -20 0 0 20 20 30 30 
Time ( min) 90 30 45 30 30 75 30 300 120 390 
Vacuum set point (MT) 100 100 100 100 100 100 100 100 100 100 
Duration of primary 
drying (hours) 
19 
 
Table 34SecondaryDrying 
Controlled parameters 
Events 
1 
Shelf temperature (0C) 40 
Time ( min) 120 
Vacuum set point (MT) 100 
Final drying temperature (0C) 40 
Duration of secondary drying (hours) 2 
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Trail 2 
Table 35 Freezing 
Controlled parameters Events 
1 2 3 4 5 6 
Shelf temperature (0C) -15 -15 -30 -30 -45 -45 
Time ( min) 5 30 30 120 30 180 
Final freeze temperature (0C) -45 
Duration of freezing (hours) 6.5 
 
Table 36Primary Drying 
Controlled 
parameters 
Events 
1 2 3 4 5 6 7 8 9 10 11 12 
Shelf 
temperature 
(0C) 
-20 -20 -15 -15 -10 -10 0 0 15 15 30 30 
Time ( min) 90 90 30 480 30 360 30 120 30 180 60 120 
Vacuum set 
point (MT) 
150 150 150 150 150 150 50 50 50 50 50 50 
Duration of 
primary drying 
(hours) 
27 
 
Table 37Secondary Drying 
Controlled parameters 
Events 
1 2 
Shelf temperature (0C) 40 40 
Time ( min) 30 480 
Vacuum set point (MT) 50 50 
Final drying temperature (0C) 40 
Duration of secondary drying (hours) 8.5 
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Trail 3 
Table 38Freezing 
Controlled parameters 
Events 
1 2 3 4 5 6 7 8 
Shelf temperature (0C) -15 -15 -20 -20 -30 -30 -45 -45 
Time ( min) 5 30 30 30 30 120 30 180 
Final freeze temperature (0C) -45 
Duration of freezing (hours) 7.58 
 
Table 39 Primary Drying 
Controlled 
parameters 
Events 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Shelf temperature 
(0C) 
-30 -30 -20 -20 -15 -15 -10 -10 0 0 20 20 30 30 
Time ( min) 30 60 120 360 120 480 60 360 60 180 60 120 120 480 
Vacuum set point 
(MT) 
150 150 150 150 150 150 150 150 150 150 100 100 50 50 
Duration of 
primary drying 
(hours) 
43.5 
 
Table 40Secondary Drying 
Controlled parameters 
Events 
1 
Shelf temperature (0C) 40 
Time ( min) 480 
Vacuum set point (MT) 50 
Final drying temperature (0C) 40 
Duration of secondary drying (hours) 8 
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7.3.2  Lyophilization F2 Formulation 
Trail 1                                                         
Table 41Freezing 
Controlled parameters 
Events 
1 2 3 4 5 6 
Shelf temperature (0C) -15 -15 -30 -30 -45 -45 
Time ( min) 5 30 30 120 90 180 
Final freeze temperature (0C) -45 
Duration of freezing (hours) 7.58 
 
Table 42Primary Drying 
Controlled 
parameters 
Events 
1 2 3 4 5 6 7 8 9 10 11 12 
Shelf temperature 
(0C) -20 -20 -15 -15 -10 -10 0 0 15 15 30 30 
Time ( min) 90 90 60 480 60 360 90 120 30 180 60 120 
Vacuum set point 
(MT) 150 150 150 150 150 150 50 50 50 50 50 50 
Duration of primary 
drying (hours) 
29 
 
Table 43Secondary Drying 
Controlled parameters Events 
1 2 
Shelf temperature (0C) 40 40 
Time ( min) 180 480 
Vacuum set point (MT) 50 50 
Final drying temperature (0C) 30 
Duration of secondary drying 
(hours) 
11 
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Trail 2 
Table 44Freezing 
Controlled parameters 
Events 
1 2 3 4 5 6 7 8 9 10 
Shelf temperature (0C) 5 5 -30 -30 -40 -40 -25 -25- -40 -40 
Time ( min) 5 10 60 90 180 180 90 180 240 360 
Final freezing temperature 
(0C) 
-40 
Duration of freezing(hours) 23.25 
 
Table 45 Primary Drying 
Controlled 
parameters 
Events 
1 2 3 4 5 6 7 8 9 10 
Shelf temperature 
(0C) 
-20 -20 -15 -15 0 0 25 25 35 35 
Time ( min) 90 160 90 180 380 360 240 240 180 180 
Vacuum set point 
(MT) 
100 100 100 100 100 100 100 100 100 100 
Duration of 
primary drying 
(hours) 
32.16 
 
Table 46 Secondary Drying 
Controlled parameters 
Events 
1 
Shelf temperature (0C) 40 
Time ( min) 850 
Vacuum set point (MT) 50 
Final drying temperature (0C) 40 
Duration of secondary drying (hours) 14.1 
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Trail 3 
Table 47 Freezing 
Controlled parameters Events 
 
1 2 3 4 5 6 7 8 9 10 
Shelf temperature (0C) 5 5 -30 -30 -45 -45 -20 -20 -45 -45 
Time ( min) 20 30 90 60 90 120 90 300 120 180 
Final freezing 
temperature (0C) 
-45 
Duration of freezing(hrs) 18.8 
 
Table48 Primary Drying 
Controlled 
parameters 
Events 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Shelf 
temperature 
(0C) 
-35 -35 -30 -30 -25 -25 -20 -20 0 0 15 15 30 30 35 0 
Time ( min) 120 180 120 180 120 180 120 180 180 360 180 360 180 360 360 0 
Vacuum set 
point (MT) 
150 150 150 150 150 150 150 150 150 150 100 100 50 50 50 0 
Duration of 
primary 
drying 
(hours) 
53 
 
 
Table 49 Secondary Drying 
Controlled parameters 
Events 
1 
Shelf temperature (0C) 35 
Time ( min) 850 
Vacuum set point (MT) 50 
Final drying temperature (0C) 30 
Duration of secondary drying (hours) 14.1 
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7.3.3  Lyophilization F3 Formulation 
Trail 1                                                         
Table 50Freezing 
Controlled parameters 
Events 
1 2 3 4 5 6 
Shelf temperature (0C) -15 -15 -30 -30 -45 -45 
Time ( min) 5 30 30 120 90 180 
Final freeze temperature (0C) -45 
Duration of freezing (hours) 7.58 
 
Table 51Primary Drying 
Controlled 
parameters 
Events 
1 2 3 4 5 6 7 8 9 10 11 12 
Shelf 
temperature 
(0C) 
-20 -20 -15 -15 -10 -10 0 0 15 15 30 30 
Time ( min) 90 90 60 480 60 360 90 120 30 180 60 120 
Vacuum set 
point (MT) 150 150 150 150 150 150 50 50 50 50 50 50 
Duration of 
primary drying 
(hours) 
29 
 
Table 52Secondary Drying 
Controlled parameters 
Events 
1 2 
Shelf temperature (0C) 40 40 
Time ( min) 180 480 
Vacuum set point (MT) 50 50 
Final drying temperature (0C) 30 
Duration of secondary drying 
(hours) 
11 
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Trail 2 
Table 53 Freezing 
Controlled 
parameters 
Events 
1 2 3 4 5 6 7 8 9 10 
Shelf temperature (0C) 5 5 -30 -30 -40 -40 -25 -25- -40 -40 
Time ( min) 5 10 60 90 180 180 90 180 240 360 
Final freezing 
temperature (0C) 
-40 
Duration of 
freezing(hrs) 
23.25 
 
Table 54 Primary Drying 
Controlled 
parameters 
Events 
1 2 3 4 5 6 7 8 9 10 
Shelf 
temperature (0C) -20 -20 -15 -15 0 0 25 25 35 35 
Time ( min) 90 160 90 180 380 360 240 240 180 180 
Vacuum set point 
(MT) 100 100 100 100 100 100 100 100 100 100 
Duration of 
primary drying 
(hours) 
32.16 
 
Table 55 Secondary Drying 
Controlled parameters 
Events 
1 
Shelf temperature (0C) 40 
Time ( min) 850 
Vacuum set point (MT) 50 
Final drying temperature (0C) 40 
Duration of secondary drying (hours) 14.1 
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Trail 3 
 
 
 
 
 
 
 
 
 
 
 
  
 Fig   9 Lyophilization cycle of F3-tail 3 formulation
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7.3.4 Lyophilization F4 Formulation 
Trail 1                                                         
Table 56Freezing 
Controlled parameters 
Events 
1 2 3 4 5 6 
Shelf temperature (0C) -15 -15 -30 -30 -45 -45 
Time ( min) 5 30 30 120 90 180 
Final freeze temperature (0C) -45 
Duration of freezing (hours) 7.58 
 
Table 57Primary Drying 
Controlled 
parameters 
Events 
1 2 3 4 5 6 7 8 9 10 11 12 
Shelf 
temperature 
(0C) 
-20 -20 -15 -15 -10 -10 0 0 15 15 30 30 
Time ( min) 90 90 60 480 60 360 90 120 30 180 60 120 
Vacuum set 
point (MT) 150 150 150 150 150 150 50 50 50 50 50 50 
Duration of 
primary 
drying(hours) 
29 
 
Table 58Secondary Drying 
Controlled parameters 
Events 
1 2 
Shelf temperature (0C) 40 40 
Time ( min) 180 480 
Vacuum set point (MT) 50 50 
Final drying temperature (0C) 30 
Duration of secondary drying (hours) 11 
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Trail 2 
Table 59Freezing 
Controlled parameters 
Events 
1 2 3 4 5 6 7 8 9 10 
Shelf temperature (0C) 5 5 -30 -30 -40 -40 -25 -25- -40 -40 
Time ( min) 5 10 60 90 180 180 90 180 240 360 
Final freezing  
temperature (0C) 
-40 
Duration of freezing(hrs) 23.25 
 
Table 60Primary Drying 
Controlled 
parameters 
Events 
1 2 3 4 5 6 7 8 9 10 
Shelf temperature 
(0C) 
-20 -20 -15 -15 0 0 25 25 35 35 
Time ( min) 90 160 90 180 380 360 240 240 180 180 
Vacuum set point 
(MT) 
100 100 100 100 100 100 100 100 100 100 
Duration of primary 
drying (hours) 
35.16 
 
Table 61Secondary Drying 
Controlled parameters 
Events 
1 
Shelf temperature (0C) 40 
Time ( min) 850 
Vacuum set point (MT) 50 
Final drying temperature (0C) 40 
Duration of secondary drying (hours) 14.1 
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Trail 3 
Table 62 Freezing 
Controlled 
parameters 
Events 
 
1 2 3 4 5 6 7 8 9 10 
Shelf temperature 
(0C) 5 5 -30 -30 -45 -45 -20 -20 -45 -45 
Time ( min) 20 30 90 60 90 120 90 300 120 180 
Final freezing 
temperature (0C) -45 
Duration of 
freezing(hrs) 
18.8 
 
Table 63 Primary Drying 
Controlled 
parameters 
Events 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Shelf 
temperature 
(0C) 
-35 -35 -30 -30 -25 -25 -20 -20 0 0 15 15 30 30 35 0 
Time ( min) 120 180 120 180 120 180 120 180 180 360 180 360 180 360 360 0 
Vacuum set 
point (MT) 150 150 150 150 150 150 150 150 150 150 100 100 50 50 50 0 
Duration of 
primary 
drying 
(hours) 
53 
 
 
Table 64 Secondary Drying 
Controlled parameters Events 
1 
Shelf temperature (0C) 35 
Time ( min) 850 
Vacuum set point (MT) 50 
Final drying temperature (0C) 30 
Duration of secondary drying (hours) 14.1 
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7.4  EVALUATION RESULTS  
Table 65 
S.NO TEST 
F 1 F 2 F 3 F 4 
T 1 T 2 T 3 T 1 T 2 T 3 T1 T2 T 3 T 1 T 2 T 3 
1 Cake appearance S S S G G G G G G G G G 
2 Clarity of 
reconstituted 
solution 
CCS CCS CCS CCS CCS CCS CCS CCS CCS CCS CCS CCS 
3 Reconstitution 
time 
15 min 16 min 15 min 7min 2min 92 sec 5min 2min 32sec 4 min 1.5 min 60 sec 
4 PH  after 
reconstitution 
2.3 2.3 2.5 2.5 2.8 2.9 2.9 2.9 3.1 3.5 3.5 3.2 
5 Water content 
(%w/w) 
5.8 5 4.2 4 2 0.99 3.6 2 0.98 1 1.6 1 
6 Assay (%) 50 55 50 70 90 96.5 85 92.5 99.5 96 91.8 97 
7 Related 
substances (%) 
3.2 3.2 3.4 3 2.1 0.25 2.5 1.8 0.248 2.5 0.99 2.5 
 
* T = Trail, CCS= Clear colorless solution, S= shrinkage, G=good 
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Fig 10Shrinkage Cake 
 
Fig 11Good cake 
 
Fig 12Cake of optimized formulation 
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7.5  ASSAY CHROMATOGRAM FOR STANDARD AND OPTIMIZED 
FORMULA  
 
 
 
 
 
 
 
Fig 13 Chromatogram of standard 
 
 
 
 
 
 
 
Fig 14Chromatogram of Optimized formulation (F3 –Trail 3) 
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7.6 DILUENT COMPATIBILITY STUDIES OF AN OPTIMIZED 
FORMULATION (F3-trail 3) 
Table66 
 
S.No 
 
Parameters 
Diluent 
Compatibility 
at250C 
Diluent 
Compatibility at 
2-80C 
Initial 3hr 24hrs 48hr 
1 Description CCS CCS CCS CCS 
2 Assay (%) 100.2 100.0 100.1 100.2 
3   Related Substances 
I BND-VI Impurity (%) ND ND ND ND 
Ii Dihyroxy Impurity (%) ND ND ND ND 
Iii Monohydroxy Impurity (%) 0.232 0.235 0.248 0.242 
Iv Monochloro Impurity (%) 0.040 0.038 0.039 0.041 
V IPA Ester Impurity (%) 0.030 0.028 0.021 0.022 
Vi Single Max (%) 0.240 0.249 0.240 0.239 
 Total (%) 0.542 0.550 0.548 0.544 
4 Osmolality (m.osm) 292 292 292 292 
 
* CCS=Clear Colorless Solution, ND=Not Detected, BEND-VI = Bendamustine, 
IPA = Isopropyl Acetate 
7.7 INNOVATOR PRODUCT DETAILS 
Table 67 Physical Parameters of Innovator Product 
Water content 1.0% 
pH 2.90 
Reconstitution time 45 Sec 
Assay 99.3% 
Related substances 0.305% 
Osmolality 295 m.osm 
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7.8 COMPARATIVE STUDY 
Table 68 Comparison of Optimized Formulation with Innovator’s 
Formulation (Treanda) 
S.No Parameters Specifications 
Innovator 
(Treanda) 
Optimized 
formulation  
(F3-TRAIL 3) 
1 Description White to half 
white lyophilized 
cake or powder 
filled in 50 ml 
vial 
White to half 
white lyophilized 
cake or powder 
filled in 50 ml vial 
White to halfwhite 
lyophilized cake or 
powderfilled in 50 
ml vial 
2 pH after 
reconstitution 2.50-3.50 2.90 3.1 
3 Reconstitution time NMT 5 min 45 sec 32 sec 
4 Water content 
(%w/w) 
NMT 3 1.0 0.98 
5 Osmolality (m.osm) 290-310 295 295 
6 Assay (%) 90-110 99.3 99.5 
7 Related substances 
i BND-IV impurity 
(%) 0.55 ND ND 
ii Dihydroxy impurity 
(%) 0.5 ND ND 
iii Monohydroxy 
impurity (%) 0.5 0.253 0.248 
iv IPAester impurity 
(%) 0.5 0.030 0.042 
v Single max (%) 1.0 0.022 0.032 
 Total (%) 3.0 0.305 0.322 
 
*NMT = Not More Than, ND = Not Detected, BEND-VI = Bendamustine, IPA 
= Isopropyl Acetate 
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7.9 STABILITY STUDIES AS PER ICH GUIDELINES  
Table 69 Accelerated Stability Study 
S.No Test parameter Specifications Initial 
400C/75 % RH 
1st Month 2nd Month 
1 Description White to off white 
lyophilized powder 
White to off white 
lyophilized powder 
White to off white 
lyophilized 
powder 
White to off white 
lyophilized powder 
2 Assay 90-110 99.5 99.5 99.4 
3 Water content(%w/w) NTM 3 0.98 0.98 0.99 
4  PH  after reconstitution 2.5-3.5 3.1 3.1 3.0 
5 Reconstitution time NTM 5 min 32 sec 32 sec 33 sec 
6 Clarity of reconstitution solution CSS CSS CSS CSS 
7 Osmolality (m.osm) 290-310 290 290 290 
8 Related substance     
 BND-IV impurity (%) 0.55 ND ND ND 
 Dihydroxy impurity (%) 0.5 ND ND ND 
 Monohydroxy impurity (%) 0.5 0.248 0.248 0.249 
 IPAester impurity (%) 0.5 0.042 0.042 0.042 
 Single max (%) 1.0 0.032 0.032 0.032 
 Total (%) NMT 3 0.322 0.324 0.324 
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Table 70Stability Data of 3rd Month under Accelerated and Long Term Storage Conditions 
 
S.No 
 
Test parameter 
 
Specifications 
400C/75 % RH 250C/60 % RH 
3rd Month 3rd Month 
1 Description  White to off white 
lyophilized powder 
White to off white 
lyophilized powder 
White to off white 
lyophilized powder 
2 Assay  90-110 99.1 99.2 
 Water content(%w/w) NTM 3 1.03 0.98 
4  PH  after reconstitution  2.5-3.5 3.1 3.1 
5 Reconstitution time  NTM 5 min 35 sec 34 sec 
6 Clarity of reconstitution solution CSS CCS CCS 
7 Osmolality (m.osm) 290-310 290 290 
8 Related substance     
 BND-IV impurity (%) 0.55 ND ND 
 Dihydroxy impurity (%) 0.5 ND ND 
 Monohydroxy impurity (%) 0.5 0.252 0.249 
 IPAester impurity (%) 0.5 0.045 0.044 
 Single max (%) 1.0 0.034 0.034 
 Total (%) NMT 3 0.331 0.327 
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7.10 PHOTOSTABILITY STUDY 
Table 71 
S.No Test parameter Initial Control (AL wrapped) 
Secondary 
peak 
Primary peak 
(delabelled) 
Primary peak 
(labelled) 
1 Description White freeze 
dried powder 
White freeze 
dried powder 
White freeze 
dried powder 
Pale yellow 
colored freeze 
dried powder 
White freeze 
dried powder 
2 Assay (%) 99.5 99.5 99.5 98.6 99.4 
3 Water content (%w/w) 0.98 0.98 0.98 0.101 0.99 
4  PH after reconstitution 3.1 3.1 3.1 3.3 3.2 
5 Reconstitution time 32 sec 32 sec 32 sec 44 sec 38 sec 
6 Clarity of reconstituted 
solution 
Clear , color 
less solution 
Clear , color 
less solution 
Clear , color 
less solution 
Clear , color less 
solution 
Clear , color 
less solution 
7 Osmolality (m.osm) 290 290 290 290 290 
8 Related substances (%) 0.322 0.322 0.322 0.456 0.35 
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8 DISCUSSION 
8.1  PREFORMULATION STUDYS 
8.1.1  Standard graph  
 Standard graph was plotted between the peak area and concentration of 
bendamustine HCL. The correlation co-efficient R2 wasfound to be 0.9994 (fig 9). 
8.1.2 Description 
 The received sample of API after visual observation it was found to show 
the white to off-white color, it is acceptable according to COA (certificate of 
analysis) 
8.1.3 Saturation Solubility studies 
a)  In water  
 The solubility of Bendamustine hydrochloride was found to be 60mg/ml. 
b)  In water and alcohol  
 Bendamustine hydrochloride solubility depends on temperature and amount 
of alcohol in aqueous solution. For the alcohol tested the solubility of bendamustine 
HCL increased as the concentration of alcohol increased. 
 Alcohols varied in their effect on solubility without washing to be bound to 
any particular theory. Smaller alcohols such as methanol and ethanol have less of an 
effect on solubility as compared with larger alcohols (TBA and n-butanol) 
 However,  the  structure  of  alcohol  is  also  important.  For  e.g.:  n-propanol  
was found to be better than iso-propanol in preventing precipitation in this system. 
The two alcohols with the greater effect as solubility were n-propanol and TBA.    
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8.1.4 Solution stability studies 
A)  Solution stability studies of 10%, 20%, 30%, 40% TBA at 250C 
 From theresults(tables 25 and 26), the following results were observed: 
Description: The  test  samples  are  clear,  colorless  solutions  at  the  end  of  
study. 
pH: The pH of the samples decreased when increasing the hold time in 
different concentration of TBA. 
Assay: Significant decrease amount of drug was observed when increasing 
the hold time at 250C 
Related substances: Significant increase in related substances was 
observed when increasing the hold time at 250C 
Conclusion:  Bendamustine Hydrochloride formulation is unstable in 
solution form in all the concentrations of TBA when stored at 250C 
 Increasing concentrations of TBA, decreasing the degradation was 
observed. 
B)  Solution stability studies of 10%, 20%, 30%, 40% TBA at 2-80C 
 From the results (tables 27 and 28), the following results were observed: 
Description: The test samples were clear, colorless solutions at the end of 
study. 
pH: The pH of the samples decreased when increasing the hold time in 
different concentration of TBA. 
Assay: Significant decrease of amount of drug was observed when 
increasing the hold time at 2-80Cin concentration of 10%TBA.  
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 There is no significant decrease of amount of drug was observedwhen 
increasing the hold time at 2-80Cin concentrations of 20%, 30%, 40% TBA. 
Related substances: Significant increase in related substances was 
observed when increasing the hold time at 2-80Cin concentrations of 
10%TBA. 
There is no significantincrease in related substances was observedwhen 
increasing the hold time at 2-80Cin concentrations of 20%, 30%, 40% TBA. 
Conclusion: Bendamustine Hydrochloride formulation is unstable in 
solution form in concentrations of 10% TBA when stored at 2-80C, whereas 
it is stable in concentrations of 20%, 30%, 40% TBA when stored at 2-80C.  
 From the results based on solution stability studies, the concentrations of 
20%, 30%, 40% TBA v/v were used further in the experiment. 
8.2  COMPATIBILITY STUDIES WITH PROCESS COMPONENTS 
8.2.1  Filter Compatibility Study 
 From the result, it was found that the assay,pH after reconstitution and 
related substances were present within the specification limits (Table 29). Hence, it 
can be concluded that PVDF filter can be used for the purpose of the filtration 
during the experimental work. 
8.2.2  Pharma Pure Tube Compatibility Study 
 From  the  results,  it  was  found  that  the  assay,pH  after  reconstitution  and  
related substances were present within the specification limits(Table 30). Hence, it 
can be concluded that Pharma tube silicon tubing can be used as processing aid 
during filtration and filling operation for transfer of liquid in pharmaceutical 
manufacturing during the experimental work. 
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8.2.3  SS Vessel Compatibility Study 
 From  the  results,  it  was  found  that  the  assay,pH  after  reconstitution  and  
related substances were present within the specification limits (Table 31). Hence SS 
Vessel was found to be compatible with the drug solution throughout the study 
period and therefore it was used for holding the drug solution before loading in to 
the lyophilizer. 
8.3  FORMULATION RESULTS  
8.3.1 Lyophilization of F1 formulation 
Trail 1 
 From the results, F1- Trail1 Formulation was formulated as mentioned in 
Table 10. The F1-Trail 1 formulation was then subjected to lyophilization as per the 
conditions shown in Tables 32–34.Initial freezing was conducted in four events for 
about 4.5 hrs with a final freezing temperature of -400C. It was then followed by 
primary drying in 10 events for 19 hrs by applying vacuum throughout the cycle. 
Finally, the secondary drying was carried out in one event for 2 hrs. 
 It was observed that after lyophilization, the cake shrinkage making it to 
collapse. This leads to poor rehydration. The possible reason could be due to  
¾ Sudden decrease in freezing temperature 
¾  Low solubility of bendamustine hydrochloride in water. 
 Therefore, further optimization was done in the lyophilization process to 
improve the cake characteristics. 
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Trail 2 
 From the results, F1-Trail 2 Formulation was formulated as mentioned in 
the Table 10. The F1- Trail 2 formulation was then subjected to lyophilization as per 
the conditions shown in Tables 35-37. Initial freezing was conducted in 6 events for 
about 6.5 hrs with a final freezing temperature of -450C. It was then followed by 
primary drying in 12 events for 27hrs by applying vacuum throughout the cycle. 
Finally, the secondary drying was carried out in 2events for 8.5 hrs. 
 It was observed that after lyophilization, the cake shrinkage making it to 
collapse. This leads to poor rehydration. The possible reason could be due to sudden 
decrease in freezing temperature, Low solubility of bendamustine hydrochloride in 
water 
 Therefore, further optimization was done in the lyophilization process to 
improve the cake 
Trail  3   
 From the Results, F1- Trail 3 Formulation was formulated as mentioned 
inTable 10.The F1- Trail 3 formulation was then subjected to lyophilization as per 
the conditions shown in Tables 38-40. Initial freezing was conducted in 8 events for 
about 7.5 hrs with a final freezing temperature of -450C. It was then followed by 
primary drying in 14events for 43.5hrs by applying vacuum throughout the cycle. 
Finally, the secondary drying was carried out in one event for 8 hrs.  
 It was observed that after lyophilization, the cake shrinkage making it to 
collapse. This leads to poor rehydration. The possible reason could be due to  
¾ Primary drying is not completed 
¾ Low solubility of bendamustine hydrochloride in water. 
 Therefore, further optimization was done in the lyophilization process to 
improve the cake characteristics. 
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8.3.2 FORMULATION 2 
Trail 1 
 From the results, F 2- Trail 1 formulations was formulated as mentioned in 
the Table 10. The F2-Trail 1 formulation was then subjected to lyophilization as per 
the conditions shown in Tables 41-43 .Initial freezing was conducted in 6 events for 
about 7.58 hrs with a final freezing temperature of -450C. It  was then followed by 
primary drying in 12 events for 29hrs by applying vacuum throughout the cycle. 
Finally, the secondary drying was carried out in one event for 11 hrs.  
 After lyophilization, the cake was found to be good but water content and 
reconstitution time obtained were not satisfactory. The possible reason could be due 
to Insufficient freezing, Insufficient duration of cycle. 
 Therefore, further optimization was doneby employing annealing technique 
in freezing process and further prolonging the cycle duration. 
Trail 2 
 From the results, F 2- Trail 2 formulations were formulated as mentioned in 
the method using the formula given in Table 10.The F2-Trail 2 formulation were 
then subjected to lyophilization as per the conditions shown in Tables 44-46. Initial 
freezing was conducted in 10 events for about 23.25hrs with a final freezing 
temperature of -450C. It was then followed by primary drying in 10 events for 32.16 
hrs by applying vacuum throughout the cycle. Finally, the secondary drying was 
carried out in 1event for 14.1 hrs. 
 After lyophilization, the water content of the formulations was found to be 
within the prescribed limit but reconstitution time and residual solvents were out of 
limits. The possible reason could be due to insufficient duration of cycle, insufficient 
drying temperature and time. 
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Trail 3 
 From the results, F2-Trail 3 formulations were formulated as mentioned in 
the method using the formula given in Table 10. The formulations were then 
subjected to lyophilization as per the conditions shown in the table 47-49. Initial 
freezing was conducted in 10 events for about 18.8hrs with a final freezing 
temperature of -450C. It was then followed by primary drying in 15 events for 53hrs 
by applying vacuum throughout the cycle. Finally, the secondary drying was carried 
out in 1event for 14.1 hrs.  
 After lyophilization, all the parameters of the formulations i.e.,Clarity, 
Reconstitution time, pH after reconstitution, water content, Assay and Related 
substances was found to be good . Through the reconstitution time was decrease 
than trai 2, further to decrease the reconstitution time the concentration of TBA: 
WFI was chaged and next trail were performed.  
8.3.3 FAROMULATION 3 
Trail 1 
 From the results, F 3- Trail 1 formulations were formulated as mentioned in 
the method using the formula given in Table 10. The F3- Trail 1 formulation were 
then subjected to lyophilization as per the conditions shown in Tables 50-52.Initial 
freezing was conducted in 6 events for about 7.58 hrs with a final freezing 
temperature of -450C. It was then followed by primary drying in 12 events for 29hrs 
by applying vacuum throughout the cycle. Finally, the secondary drying was carried 
out in one event for 11 hrs. 
 After lyophilization, the cake was found to be good but water content and 
reconstitution time obtained were not satisfactory. The possible reason could be due 
to Insufficient freezing, Insufficient duration of cycle. 
 Therefore, further optimization was doneby employing annealing technique 
in freezing process and further prolonging the cycle duration. 
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Trail 2 
 From the results, F3-Trail 2 formulations were formulated as mentioned in 
the method using the formula given in Table 10.The F3-taril 2 formulation were then 
subjected to lyophilization as per the conditions shown in Tables 53-55. Initial 
freezing was conducted in 10 events for about 23.25hrs with a final freezing 
temperature of -450C. It was then followed by primary drying in 10 events for 32.16 
hrs by applying vacuum throughout the cycle. Finally, the secondary drying was 
carried out in 1event for 14.1 hrs. 
 After lyophilization, the water content of the formulations was found to be 
within the prescribed limit but reconstitution time and residual solvents were out of 
limits. The possible reason could be due to insufficient duration of cycle, insufficient 
drying temperature and time. 
Trail 3 
 From the results, F3-Trail 3formulationswere formulated as mentioned in 
Table  10.  The  formulations  were  then  subjected  to  lyophilization  as  per  the  
conditions shown in the fig 9. Initial freezing was conducted in 10 events for about 
18.8hrs with a final freezing temperature of -450C. It was then followed by primary 
drying in 15 events for 51.3hrs by applying vacuum throughout the cycle. Finally, 
the secondary drying was carried out in 1event for 14.1 hrs. 
 The reconstitution was 32 sec which was found satisfactory with change in 
TBA: WFI and cycle changed  
 Further to see the improvement formulation 4 with TBA: WFI (80:120) 
was prepared  
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8.3.4 FAROMULATION 4 
Trail 1 
 From the results, F4-Trail 1 formulations were formulated as mentioned in 
Table 10. The F4-Trail 1 formulation were then subjected to lyophilization as per the 
conditions shown in Tables 56-58 .Initial freezing was conducted in 6 events for 
about 7.58 hrs with a final freezing temperature of -450C. It  was then followed by 
primary drying in 12 events for 29hrs by applying vacuum throughout the cycle. 
Finally, the secondary drying was carried out in one event for 11 hrs. 
 After lyophilization, the cake was found to be good but water content and 
reconstitution time obtained were not satisfactory. The possible reason could be due 
to Insufficient freezing, Insufficient duration of cycle. 
 Therefore, further optimization was doneby employing annealing technique 
in freezing process and further prolonging the cycle duration. 
Trail 2 
 From the results, F4-Trail 2 formulations were formulated as mentioned in 
Table 10.The F4-Trail 2 formulation were then subjected to lyophilization as per the 
conditions shown in Tables 59-61. Initial freezing was conducted in 10 events for 
about 23.25hrs with a final freezing temperature of -450C. It was then followed by 
primary drying in 10 events for 32.16 hrs by applying vacuum throughout the cycle. 
Finally, the secondary drying was carried out in 1event for 14.1 hrs. 
 After lyophilization, the water content of the formulations was found to be 
within the prescribed limit but reconstitution time and residual solvents were out of 
limits. The possible reason could be due to insufficient duration of cycle, insufficient 
drying temperature and time. 
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Trail 3 
 From the results, F4-Trail 3 formulations were formulated as mentioned in 
Table  10.  The  formulations  were  then  subjected  to  lyophilization  as  per  the  
conditions shown in the tables 62-64. Initial freezing was conducted in 10 events for 
about 18.8hrs with a final freezing temperature of -450C. It was then followed by 
primary drying in 15 events for 53 hrs by applying vacuum throughout the cycle. 
Finally, the secondary drying was carried out in 1event for 14.1 hrs. 
 This formulation also shows same reconstitution time as formulation 
formulation 3 trail 3 
 Depending upon the concentration of solvents formulation 3-trail 3 was 
taken as optimized formulation 
8.4 EVALUATION RESULTS 
 From the data illustrated in the Table 65, it was observed that the clarity of 
all the formulations was clear and pH (2.5-3.5) was within the prescribed limits. In 
F1-Trail 1, Trail 2, Trail 3 formulations shrinkage of the cake was observed as 
shown in the fig 10, but from formulation F2-trail 1 to F4- trail 3, it was found to be 
good as shown in the fig 11. The water content of the formulations F3Trai 1 to F4- 
trai 3 was within the prescribed limits (NMT 3%). From formulations F2 –trail 2 to 
F4- trail 3, the presence of related substances (2.5%) was found to be within the 
limits. The assay (90-110%) of the formulations F2-tail 3, F3-trail 3, F4- trail 3 was 
found to be better. Among all the formulations the reconstitution of the formulation 
F3-trail 3 was found to be the best. 
 Therefore, it can be evidently concluded that the formulation F3-Trail3 was 
the best formulation (Fig 12). Chromatogram of assay of an optimized formulation 
F3-Trail3 was illustrated in the figure 14. 
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8.5 DILUENT COMPATIBILITY STUDIES OF AN OPTIMIZED 
FORMULATION (F3-trail 3) 
 From the results Table 66, it was observed that the reconstituted lyophilized 
product was compatible with 0.9% sodium chloride solution. No incompatibility was 
observed in the diluent and formulation. The drug solution was stable for 3hrs when 
stored at 250C and for 48 hrs at 2-80C. 
8.6 COMPARISION OF OPTIMIZED FORMULATION WITH 
 INNOVATOR’S FORMULATION (TREANDA) 
 The test parameters like pH after reconstitution, Reconstitution time, Water 
content, Assay, Osmolality and Related substances of the optimized formulation was 
compared with innovators drug product. From the results (table 68) it was found that 
the formulation was similar with that of innovator. 
8.7 STABILITY STUDIES AS PER ICH GUIDELINES 
 ACCELERATED STABILITY STUDY 
 From the results Tables 69 and 70, The accelerated and long term stability 
study results confirms that the test parameters like pH after reconstitution, 
Reconstitution time,Water content, Assay, Osmolality and Related substances were 
found to be within the specification limits. So, it can be concluded that the 
lyophilized drug was stable at accelerated and long term storage conditions of 
40°C/75 % RH and 25°C/60 % RH respectively for a period of 3 months. 
8.8 PHOTOSTABILITY STUDY 
 From the results Table 71, the photo stability study results confirm that the 
test parameters like pH after reconstitution, Reconstitution time, Water content, 
Assay, Osmolality and Related substances were found to be within the specification 
limit. Hence the photo stability study on the drug product confirmed that the product 
was stable when exposed to the light in its primary packing. 
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SUMMARY & CONCLUSION 
 Bendamustine Hydrochloride is unstable in the solution form. So, it cannot 
be formulated as a liquid dosage form. In order to improve its stability, the drug 
product should be dried and formulated as a solid product. Even though there are 
several drying techniques to dry a product, lyophilization technique was preferred 
for drying this product because it involves the drying of the product at low 
temperature and low pressure. As Bendamustine Hydrochloride is thermolabile in 
nature and cannot withstand elevated temperatures, this technique is the best choice 
to increase its stability. 
 Preformulation studies were done by conducting solution stability studies at 
different concentrations of TBA (10%, 20%, 30%, and 40%) at 25°C and 2-8°C 
upto 24hrs. From these studies it was found that the drug solution was unstable in all 
concentrations of TBA at 25°C and in 10%TBA at 2-8°C. So, further studies were 
carried out with 20%, 30% and 40% TBA at 2-8°C. 
 Initially an injectable dosage form of the drug product was developed and 
the compatibility of this drug solution with various process components was studied. 
The drug was found tobe compatible with the used materials (SS Vessel, 
pharmapure silicon tube, PVDF filter). 
 The  thermal  characteristics  of  the  product  were  studied  and  based  on  that  
different lyophilization cycles have been developed by varying temperature, 
pressure and duration of the cycle. The final temperatures set for the optimized 
formulation was able to withstand freeze thaw cycles without effecting the quality of 
the product. The freezing, primary drying and secondary drying temperatures used 
were -45°C, 35°C and 35°C respectively, the pressure during the process was set as 
150-50mTorr and the total run time of the cycle was 84.2 hours. 
 The formed lyophilized cake was evaluated for its appearance, water 
content, assay, reconstitution time, pH and related substances. All these parameters 
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were found to be within the specifications thus confirming that the developed 
lyophilization cycle was proved to be satisfactory. 
 The reconstitution stability studies showed that the developed lyophilized 
product can be reconstituted with the innovator recommended diluents such as 0.9% 
sodium chloride injection within a specified time. 
 The  results  of  the  optimized  formulation  was  found to  be  good as  that  of  
innovator. 
 The photo stability study on the drug product confirmed that the product 
was stable when exposed to the light in its primary packing. 
CONCLUSION 
 The lyophilized technique proved to be an advantage for development of 
stable injectable dosage form of Bendamustine Hydrochloride as the moisture 
content of the formulation was greatly reduced to as low as 0.98% (w/w) thus 
enhancing the stability of the product.However, further work in this field of study 
require in order to make the drug available in the market. 
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